https://www.trinitydelta.org/savolitinib-lung-cancer-progress-and-kidney-cancer-strategy-update/ 2019-01-29T13:25:42+00:00 https://www.trinitydelta.org/first-commercial-launch-of-fruquintinib-capsules-elunate/ 2019-01-29T13:31:19+00:00 https://www.trinitydelta.org/phase-iii-faluca-results-for-fruquintinib-in-third-line-advanced-nsclc-in-china/ 2019-01-29T13:33:44+00:00 https://www.trinitydelta.org/china-approval-of-fruquintinib-for-mcrc/ 2019-01-29T13:38:04+00:00 https://www.trinitydelta.org/2018-interim-results-and-clinical-update/ 2019-01-29T13:40:09+00:00 https://www.trinitydelta.org/further-fruquintinib-fresco-trial-data-at-asco-2018/ 2019-01-29T13:41:57+00:00 https://www.trinitydelta.org/2017-final-results-and-clinical-update/ 2019-01-29T13:47:01+00:00 https://www.trinitydelta.org/initiation-of-us-sulfatinib-phase-ib-ii-trial-in-pancreatic-net-and-btc/ 2019-01-29T13:48:50+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-trial-of-hmpl-523-azacitidine-in-elderly-aml/ 2019-01-29T13:50:09+00:00 https://www.trinitydelta.org/amendment-to-2013-eli-lilly-fruquintinib-license-and-collaboration-deal/ 2019-01-29T13:51:37+00:00 https://www.trinitydelta.org/multiple-collaborations-to-evaluate-pd-1-combinations-with-surufatinib-and-fruquintinib/ 2019-01-29T13:53:09+00:00 https://www.trinitydelta.org/preliminary-phase-ii-savolitinib-imfinzi-prcc-data-at-2019-asco-gu/ 2019-02-12T13:40:01+00:00 https://www.trinitydelta.org/update-on-cruk-grand-challenge/ 2019-02-12T14:52:30+00:00 https://www.trinitydelta.org/interim-h119-results/ 2019-02-12T14:54:20+00:00 https://www.trinitydelta.org/appointment-of-head-of-research-and-head-of-manufacturing/ 2019-02-12T14:55:55+00:00 https://www.trinitydelta.org/modi-2-extension-of-moditope-platform/ 2019-02-12T15:04:39+00:00 https://www.trinitydelta.org/sc1b-ind-update/ 2019-02-12T15:07:21+00:00 https://www.trinitydelta.org/fy18-results-2/ 2019-02-12T15:12:20+00:00 https://www.trinitydelta.org/board-change/ 2019-02-12T15:13:56+00:00 https://www.trinitydelta.org/extension-of-karolinska-research-collaboration/ 2019-02-12T15:15:46+00:00 https://www.trinitydelta.org/issue-of-equity-to-ichor/ 2019-02-12T15:17:05+00:00 https://www.trinitydelta.org/option-exercise-for-trigrid-from-ichor/ 2019-02-12T15:18:50+00:00 https://www.trinitydelta.org/european-patent-granted-for-moditope-platform/ 2019-02-12T15:20:58+00:00 https://www.trinitydelta.org/2018-final-results-and-clinical-update/ 2019-03-13T16:28:53+00:00 https://www.trinitydelta.org/ip-portfolio-strengthened/ 2019-03-21T13:25:17+00:00 https://www.trinitydelta.org/cso-receives-waldenstrom-award-from-swedish-society-of-oncology/ 2019-03-21T13:26:50+00:00 https://www.trinitydelta.org/2018-annual-report-and-notice-of-agm/ 2019-03-29T16:24:05+00:00 https://www.trinitydelta.org/oral-presentations-on-savolitinib-lung-cancer-programs-at-aacr/ 2019-03-29T16:25:34+00:00 https://www.trinitydelta.org/initiation-of-surufatinib-china-phase-iib-iii-in-unresectable-or-metastatic-btc/ 2019-03-29T16:28:08+00:00 https://www.trinitydelta.org/grant-of-japanese-patent-that-protects-moditope-immunotherapy-platform/ 2019-04-12T11:07:57+00:00 https://www.trinitydelta.org/application-to-list-in-hong-kong-and-proposed-global-offering/ 2019-04-15T21:52:00+00:00 https://www.trinitydelta.org/uk-regulatory-approval-to-start-scib1-phase-ii-advanced-melanoma-trial/ 2019-04-25T13:44:55+00:00 https://www.trinitydelta.org/establishment-of-clinical-advisory-board-and-update-on-modi1-progress/ 2019-05-28T13:33:41+00:00 https://www.trinitydelta.org/update-on-sc1b2-development/ 2019-05-28T13:35:45+00:00 https://www.trinitydelta.org/results-of-egm/ 2019-05-29T15:30:49+00:00 https://www.trinitydelta.org/share-subscription-and-issue-of-equity-to-vulpes-life-sciences-fund/ 2019-06-13T11:24:12+00:00 https://www.trinitydelta.org/surufatinib-phase-iii-sanet-ep-study-meets-primary-endpoint-at-interim-analysis-and-will-stop-early/ 2019-06-14T12:31:07+00:00 https://www.trinitydelta.org/board-appointment/ 2019-06-26T12:24:53+00:00 https://www.trinitydelta.org/pricing-of-upsized-us-public-secondary-offering-of-ads/ 2019-06-28T15:52:43+00:00 https://www.trinitydelta.org/chi-med-announces-secondary-offering-of-ads/ 2019-06-28T15:53:28+00:00 https://www.trinitydelta.org/h1-2019-business-update/ 2019-07-01T14:18:21+00:00 https://www.trinitydelta.org/chi-med-to-announce-h119-financial-results/ 2019-07-19T10:11:47+00:00 https://www.trinitydelta.org/2019-interim-results-and-clinical-update/ 2019-07-30T10:20:18+00:00 https://www.trinitydelta.org/scib1-study-update/ 2019-08-21T14:26:08+00:00 https://www.trinitydelta.org/fy19-preliminary-results/ 2019-08-21T14:29:02+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-trial-of-hmpl-523-in-immune-thrombocytopenia-itp/ 2019-08-28T13:30:14+00:00 https://www.trinitydelta.org/first-collaboration-agreement-for-its-new-platform-technology-avidimab/ 2019-09-04T14:50:35+00:00 https://www.trinitydelta.org/oral-presentations-at-2019-csco-annual-meeting/ 2019-09-19T13:53:44+00:00 https://www.trinitydelta.org/presentation-of-clinical-data-from-the-successful-phase-iii-sanet-ep-trial-at-esmo/ 2019-09-26T15:30:19+00:00 https://www.trinitydelta.org/six-posters-at-the-cri-cimt-eati-aacr-international-cancer-immunotherapy-conference/ 2019-09-26T15:34:40+00:00 https://www.trinitydelta.org/chi-med-to-discuss-surufatinib-phase-iii-and-us-phase-i-ib-efficacy-and-safety-data-presented-at-esmo/ 2019-10-02T10:05:46+00:00 https://www.trinitydelta.org/ck-hutchison-prices-1-3-chi-med-share-offering-enabling-deconsolidation-confirms-intention-to-hold-chi-med-as-a-long-term-strategic-investment/ 2019-10-02T10:09:59+00:00 https://www.trinitydelta.org/initiation-of-international-phase-i-ib-trial-of-hmpl-523-in-advanced-relapsed-or-refractory-lymphoma/ 2019-10-08T14:36:36+00:00 https://www.trinitydelta.org/global-collaboration-with-innovent-expanded-to-include-surufatinib/ 2019-10-10T08:26:25+00:00 https://www.trinitydelta.org/publication-of-phase-ii-data-showing-promising-efficacy-for-savolitinib-in-met-amplified-gastric-cancers/ 2019-10-23T12:24:41+00:00 https://www.trinitydelta.org/nda-acceptance-in-china-for-surufatinib-in-non-pancreatic-net/ 2019-11-11T13:52:05+00:00 https://www.trinitydelta.org/recruitment-completed-for-med2005-phase-iii-study/ 2019-11-22T13:43:32+00:00 https://www.trinitydelta.org/joint-venture-collaboration-announced/ 2019-11-22T13:44:02+00:00 https://www.trinitydelta.org/interim-h119-results-2/ 2019-11-22T13:44:31+00:00 https://www.trinitydelta.org/final-dosing-of-last-patient-in-med2005-phase-iii-study/ 2019-11-22T13:45:06+00:00 https://www.trinitydelta.org/med2005-safety-and-efficacy-data-at-smsna/ 2019-11-22T13:45:43+00:00 https://www.trinitydelta.org/publishes-fireside-chat-with-prof-wayne-hellstrom/ 2019-11-22T13:49:54+00:00 https://www.trinitydelta.org/surufatinib-granted-fda-orphan-drug-designation-for-pancreatic-net/ 2019-11-28T14:16:06+00:00 https://www.trinitydelta.org/elunate-fruquintinib-included-in-the-china-nrdl/ 2019-11-28T14:17:38+00:00 https://www.trinitydelta.org/top-line-results-from-med2005-phase-iii-study/ 2019-12-10T07:46:41+00:00 https://www.trinitydelta.org/new-european-moditope-patent-allowed-for-grant/ 2019-12-16T14:16:39+00:00 https://www.trinitydelta.org/second-agreement-signed-for-avidimab-platform/ 2019-12-16T14:18:07+00:00 https://www.trinitydelta.org/corporate-update-and-proposed-fundraise-of-3-25m/ 2019-12-30T09:15:07+00:00 https://www.trinitydelta.org/result-of-fundraise/ 2019-12-30T09:19:35+00:00 https://www.trinitydelta.org/posting-of-circular-and-notice-of-general-meeting/ 2019-12-30T09:21:15+00:00 https://www.trinitydelta.org/surufatinib-nda-in-non-pancreatic-net-granted-priority-review-in-china/ 2019-12-30T09:38:21+00:00 https://www.trinitydelta.org/initiation-of-phase-ii-trial-of-surufatinib-in-combination-with-tuoyi-in-patients-with-advanced-solid-tumours/ 2020-01-13T15:39:12+00:00 https://www.trinitydelta.org/surufatinib-phase-iii-sanet-p-study-meets-primary-endpoint-at-interim-analysis-and-will-stop-early/ 2020-01-20T14:06:02+00:00 https://www.trinitydelta.org/third-agreement-signed-for-antibody-platform/ 2020-01-20T14:08:05+00:00 https://www.trinitydelta.org/result-of-general-meeting/ 2020-01-20T14:09:53+00:00 https://www.trinitydelta.org/proposed-public-offering-of-adss/ 2020-01-22T11:10:42+00:00 https://www.trinitydelta.org/pricing-of-110m-public-offering-of-adss/ 2020-01-23T14:55:18+00:00 https://www.trinitydelta.org/h120-interim-results-2/ 2020-01-31T10:43:35+00:00 https://www.trinitydelta.org/scib1-ind-application-approved/ 2020-02-03T20:46:30+00:00 https://www.trinitydelta.org/exercise-of-underwriters-over-allotment-option-for-public-ads-offering/ 2020-02-10T20:06:28+00:00 https://www.trinitydelta.org/updated-phase-ii-savolitinib-imfinzi-combination-data-in-advanced-prcc-at-asco-gu-2020/ 2020-02-10T20:08:55+00:00 https://www.trinitydelta.org/update-on-positive-eu-regulatory-discussions-and-further-ongoing-analysis-of-fm57/ 2020-02-13T09:58:02+00:00 https://www.trinitydelta.org/fm57-clinical-data-and-med3000-update-at-investor-seminar-in-march-2020/ 2020-03-12T17:16:42+00:00 https://www.trinitydelta.org/fy19-results-and-clinical-update/ 2020-03-12T17:21:39+00:00 https://www.trinitydelta.org/initiation-of-china-phase-ii-trial-of-hmpl-453-in-advanced-malignant-mesothelioma/ 2020-03-31T09:03:24+00:00 https://www.trinitydelta.org/fy19-results-2/ 2020-04-01T07:22:58+00:00 https://www.trinitydelta.org/futura-confirms-receipt-of-us-fda-minutes/ 2020-04-06T14:08:47+00:00 https://www.trinitydelta.org/surufatinib-granted-fda-fast-track-designations-for-nets/ 2020-04-17T08:43:45+00:00 https://www.trinitydelta.org/futura-files-for-further-fda-pre-submission-meeting/ 2020-04-20T08:07:08+00:00 https://www.trinitydelta.org/surufatinib-presentations-at-upcoming-aacr-virtual-annual-meetings/ 2020-04-22T08:59:17+00:00 https://www.trinitydelta.org/development-of-vaccine-against-covid-19/ 2020-04-24T12:31:54+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-asco-2020/ 2020-05-14T13:08:14+00:00 https://www.trinitydelta.org/clinical-collaboration-with-beigene/ 2020-05-26T10:59:01+00:00 https://www.trinitydelta.org/savolitinib-china-nda-acceptance-for-nsclc-with-met-ex14-skipping-mutations/ 2020-06-01T07:20:43+00:00 https://www.trinitydelta.org/plans-to-submit-us-nda-for-surufatinib-following-fda-pre-nda-meeting/ 2020-06-01T07:22:43+00:00 https://www.trinitydelta.org/continuation-of-china-phase-iii-frutiga-study-of-fruquintinib-in-2l-gastric-cancer/ 2020-06-04T07:24:00+00:00 https://www.trinitydelta.org/us95m-guangzhou-land-compensation-agreement/ 2020-06-09T08:56:49+00:00 https://www.trinitydelta.org/cancer-research-publication-highlights-potential-of-avidimab/ 2020-06-12T12:52:26+00:00 https://www.trinitydelta.org/fruquintinib-granted-fda-fast-track-designation-for-mcrc/ 2020-06-18T13:01:52+00:00 https://www.trinitydelta.org/trading-statement/ 2020-06-24T07:42:03+00:00 https://www.trinitydelta.org/publication-highlights-potential-of-modi-1/ 2020-06-24T12:33:02+00:00 https://www.trinitydelta.org/us100m-equity-investment-by-general-atlantic/ 2020-06-25T10:01:57+00:00 https://www.trinitydelta.org/eu-and-us-regulatory-update/ 2020-07-14T16:25:27+00:00 https://www.trinitydelta.org/proposed-capital-raise-to-raise-up-to-15m/ 2020-07-22T08:27:20+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-trial-of-idh1-2-dual-inhibitor-in-haematological-malignancies/ 2020-07-28T07:26:15+00:00 https://www.trinitydelta.org/china-nda-for-savolitinib-in-nsclc-granted-priority-review/ 2020-07-28T07:27:27+00:00 https://www.trinitydelta.org/chi-med-and-eli-lilly-to-collaborate-in-commercializing-elunate-in-china/ 2020-07-28T07:30:32+00:00 https://www.trinitydelta.org/h120-interims-and-clinical-update/ 2020-08-03T12:36:04+00:00 https://www.trinitydelta.org/update-on-cbd100-first-stage-development-work/ 2020-08-04T16:25:35+00:00 https://www.trinitydelta.org/plans-to-submit-surufatinib-maa-following-ema-chmp-scientific-advice/ 2020-08-10T08:06:21+00:00 https://www.trinitydelta.org/positive-qms-audit-opinion-received/ 2020-08-10T08:20:38+00:00 https://www.trinitydelta.org/shareholder-circular/ 2020-08-13T10:36:46+00:00 https://www.trinitydelta.org/results-of-general-meeting/ 2020-08-13T10:37:53+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-the-upcoming-esmo-virtual-congress-2020/ 2020-08-24T07:28:34+00:00 https://www.trinitydelta.org/covid-19-vaccine-awarded-funding-by-innovate-uk/ 2020-08-27T11:21:14+00:00 https://www.trinitydelta.org/initiation-of-hmpl-453-china-phase-ii-in-advanced-intrahepatic-cholangiocarcinoma/ 2020-09-03T16:18:51+00:00 https://www.trinitydelta.org/initiation-of-global-fruquintinib-fresco-2-phase-iii-in-mcrc/ 2020-09-04T08:27:36+00:00 https://www.trinitydelta.org/new-research-collaboration-with-jazz-pharmaceuticals/ 2020-09-14T07:41:30+00:00 https://www.trinitydelta.org/fy19-results-and-operational-update/ 2020-09-14T07:41:53+00:00 https://www.trinitydelta.org/redmile-loan-announcement/ 2020-09-14T07:42:08+00:00 https://www.trinitydelta.org/result-of-agm-and-operational-update/ 2020-09-14T07:42:24+00:00 https://www.trinitydelta.org/h120-interim-results-3/ 2020-09-14T07:42:38+00:00 https://www.trinitydelta.org/proposed-30m-financing-via-issue-of-clns-and-share-subscription/ 2020-09-14T07:42:53+00:00 https://www.trinitydelta.org/out-licensing-agreement-with-astrazeneca/ 2020-09-14T07:43:06+00:00 https://www.trinitydelta.org/h120-interim-results-4/ 2020-09-16T07:05:06+00:00 https://www.trinitydelta.org/acceptance-of-second-china-nda-for-surufatinib-in-pnet/ 2020-09-17T14:14:43+00:00 https://www.trinitydelta.org/surufatinib-phase-iii-data-in-nets-at-esmo-2020-and-publication-in-the-lancet-oncology/ 2020-09-21T09:37:12+00:00 https://www.trinitydelta.org/interim-results-for-the-6-months-ended-december-2019/ 2020-09-23T06:42:44+00:00 https://www.trinitydelta.org/eaaci-review-of-adjuvants-and-formulations/ 2020-09-23T06:43:02+00:00 https://www.trinitydelta.org/update/ 2020-09-23T06:43:23+00:00 https://www.trinitydelta.org/invalidation-of-birch-mata-mpl-phase-iii-results/ 2020-09-23T06:43:41+00:00 https://www.trinitydelta.org/fy20-trading-update/ 2020-09-23T06:43:59+00:00 https://www.trinitydelta.org/allergy-therapeutics-secures-vlp-technology-platform/ 2020-09-23T06:44:19+00:00 https://www.trinitydelta.org/fy20-preliminary-results/ 2020-09-23T06:45:34+00:00 https://www.trinitydelta.org/collaboration-to-manufacture-covid-19-vaccine/ 2020-10-02T15:06:08+00:00 https://www.trinitydelta.org/proposed-investment-by-redmile-and-open-offer/ 2020-10-12T09:57:24+00:00 https://www.trinitydelta.org/final-results-for-year-ended-30-april-2020/ 2020-10-16T17:03:06+00:00 https://www.trinitydelta.org/regulatory-and-commercial-update-for-med3000/ 2020-10-22T07:26:48+00:00 https://www.trinitydelta.org/initiation-of-grass-mata-mpl-exploratory-study/ 2020-10-26T08:41:21+00:00 https://www.trinitydelta.org/appointment-of-chief-medical-officer/ 2020-10-27T09:11:47+00:00 https://www.trinitydelta.org/conversion-of-clns/ 2020-10-30T15:12:49+00:00 https://www.trinitydelta.org/result-of-open-offer-and-adjournment-of-general-meeting/ 2020-10-30T15:14:14+00:00 https://www.trinitydelta.org/hmpl-689-clinical-data-to-be-presented-at-ash-2020/ 2020-11-05T15:44:20+00:00 https://www.trinitydelta.org/result-of-adjourned-general-meeting/ 2020-11-05T15:46:44+00:00 https://www.trinitydelta.org/conversion-of-clns-and-total-voting-rights/ 2020-11-05T15:47:40+00:00 https://www.trinitydelta.org/appointment-of-cmo-and-medical-director/ 2020-11-17T12:12:42+00:00 https://www.trinitydelta.org/us100m-equity-investment-by-cpp-investments/ 2020-11-17T12:13:51+00:00 https://www.trinitydelta.org/25-5m-placing-and-open-offer/ 2020-12-02T09:56:08+00:00 https://www.trinitydelta.org/us-regulatory-and-commercial-update/ 2020-12-08T13:33:57+00:00 https://www.trinitydelta.org/ground-breaking-ceremony-for-shanghai-manufacturing-plant/ 2020-12-08T13:40:16+00:00 https://www.trinitydelta.org/covid-19-vaccine-candidate-selected/ 2020-12-18T08:18:48+00:00 https://www.trinitydelta.org/results-of-open-offer-and-general-meeting/ 2020-12-22T08:50:28+00:00 https://www.trinitydelta.org/china-approval-of-surufatinib-in-epnet/ 2020-12-30T15:05:36+00:00 https://www.trinitydelta.org/initiation-of-rolling-nda-submission-for-surufatinib-in-nets/ 2020-12-31T11:50:16+00:00 https://www.trinitydelta.org/initiation-of-peanut-allergy-biomarker-study/ 2021-01-05T08:14:51+00:00 https://www.trinitydelta.org/strategic-partnership-with-inmagene-for-drug-candidate-portfolio-for-immunological-diseases/ 2021-01-11T08:14:34+00:00 https://www.trinitydelta.org/h121-trading-update-and-notice-of-results/ 2021-01-13T07:55:34+00:00 https://www.trinitydelta.org/savolitinib-clinical-data-to-be-presented-at-virtual-wclc/ 2021-01-20T09:21:17+00:00 https://www.trinitydelta.org/fy20-results-and-operational-update/ 2021-01-27T13:35:29+00:00 https://www.trinitydelta.org/interim-results-for-six-months-ended-31-october-2020/ 2021-01-29T11:44:30+00:00 https://www.trinitydelta.org/update-on-scib2-clinical-development-partnership/ 2021-02-03T19:58:32+00:00 https://www.trinitydelta.org/interim-h121-results/ 2021-03-03T07:57:43+00:00 https://www.trinitydelta.org/investment-and-joint-collaboration/ 2021-03-04T07:51:07+00:00 https://www.trinitydelta.org/fy20-results-business-update/ 2021-03-04T12:33:26+00:00 https://www.trinitydelta.org/recommendation-for-approval-of-med3000-from-eu-notified-body/ 2021-03-19T08:25:28+00:00 https://www.trinitydelta.org/fda-agreement-for-confirmatory-clinical-study/ 2021-03-22T13:26:37+00:00 https://www.trinitydelta.org/169m-agreement-to-divest-non-core-otc-jv/ 2021-03-24T16:11:58+00:00 https://www.trinitydelta.org/100m-equity-investment-by-baring-private-equity-asia/ 2021-04-08T09:33:08+00:00 https://www.trinitydelta.org/fy20-results/ 2021-04-14T07:57:33+00:00 https://www.trinitydelta.org/conversion-of-convertible-loan-notes/ 2021-04-15T15:04:37+00:00 https://www.trinitydelta.org/first-patients-dosed-with-rx004-and-anti-pd-1/ 2021-04-28T09:13:26+00:00 https://www.trinitydelta.org/receipt-of-med3000-approval-from-eu-notified-body/ 2021-04-30T08:56:38+00:00 https://www.trinitydelta.org/initiation-of-china-phase-ii-registration-study-of-hmpl-689-in-lymphoma/ 2021-04-30T08:59:07+00:00 https://www.trinitydelta.org/completion-of-fda-rolling-nda-submission-for-surufatinib-in-advanced-net/ 2021-05-04T11:29:29+00:00 https://www.trinitydelta.org/appointment-of-peter-collum-as-cfo/ 2021-05-05T07:09:13+00:00 https://www.trinitydelta.org/completion-of-treatment-phase-in-g309-study/ 2021-05-06T08:05:44+00:00 https://www.trinitydelta.org/update-on-submission-for-fda-clearance/ 2021-05-10T21:29:03+00:00 https://www.trinitydelta.org/global-launch-of-clinical-services-laboratories/ 2021-05-10T21:29:26+00:00 https://www.trinitydelta.org/first-large-scale-pharma-services-contract-secured/ 2021-05-10T21:29:43+00:00 https://www.trinitydelta.org/completion-of-enrolment-in-ovarian-cancer-study/ 2021-05-10T21:30:00+00:00 https://www.trinitydelta.org/fy20-preliminary-results-2/ 2021-05-10T21:30:16+00:00 https://www.trinitydelta.org/proposed-placing-to-raise-10-million-and-retail-offer/ 2021-05-17T08:24:30+00:00 https://www.trinitydelta.org/result-of-placing-and-retail-offer/ 2021-05-17T08:25:45+00:00 https://www.trinitydelta.org/parsortix-demonstrates-oesophageal-cancer-utility/ 2021-05-25T16:46:07+00:00 https://www.trinitydelta.org/parsortix-study-uncovers-targets-in-tnbc-patients/ 2021-05-25T16:48:04+00:00 https://www.trinitydelta.org/potential-to-prevent-breast-cancer-relapse/ 2021-06-07T08:24:50+00:00 https://www.trinitydelta.org/update-on-submission-for-fda-clearance-2/ 2021-06-07T08:25:46+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-asco-2021/ 2021-06-07T08:33:02+00:00 https://www.trinitydelta.org/first-subject-dosed-in-rxc007-phase-i-study/ 2021-06-07T08:39:37+00:00 https://www.trinitydelta.org/interim-h121-results-2/ 2021-06-07T08:40:37+00:00 https://www.trinitydelta.org/receipt-of-4m-rxc004-milestone-payment/ 2021-06-17T09:51:37+00:00 https://www.trinitydelta.org/launch-of-hong-kong-ipo/ 2021-06-20T21:13:10+00:00 https://www.trinitydelta.org/china-nmpa-approval-of-surufatinib-for-advanced-pnet/ 2021-06-20T21:16:30+00:00 https://www.trinitydelta.org/covidity-phase-i-trial-planned-in-south-africa-and-uk/ 2021-06-22T08:51:19+00:00 https://www.trinitydelta.org/china-approval-of-savolitinib-for-nsclc-with-met-exon-14-skipping-alterations/ 2021-06-23T18:36:55+00:00 https://www.trinitydelta.org/pricing-of-global-offering/ 2021-06-23T18:39:04+00:00 https://www.trinitydelta.org/pre-close-trading-update/ 2021-06-24T06:32:11+00:00 https://www.trinitydelta.org/accelerated-bookbuild-to-raise-up-to-20m-gross/ 2021-06-24T20:20:31+00:00 https://www.trinitydelta.org/ctdna-and-ctcs-have-differences-in-egfr-mutations/ 2021-06-24T20:22:48+00:00 https://www.trinitydelta.org/result-of-accelerated-bookbuild/ 2021-06-27T19:43:09+00:00 https://www.trinitydelta.org/affidx-sars-cov-2-antigen-lft-detects-delta-variant/ 2021-06-29T13:04:06+00:00 https://www.trinitydelta.org/affidx-sars-cov-2-antigen-lft-distribution-agreement/ 2021-06-29T13:05:41+00:00 https://www.trinitydelta.org/eu-registration-of-affidx-sars-cov-2-antigen-lft/ 2021-06-29T13:06:52+00:00 https://www.trinitydelta.org/mhra-confirms-registration-of-affidx-sars-cov-2-antigen-lft/ 2021-06-29T13:07:47+00:00 https://www.trinitydelta.org/preliminary-fy20-results/ 2021-06-29T13:09:02+00:00 https://www.trinitydelta.org/closing-of-global-offering-and-primary-listing-in-hong-kong/ 2021-07-01T16:02:25+00:00 https://www.trinitydelta.org/fda-acceptance-of-surufatinib-nda-for-advanced-nets/ 2021-07-01T16:03:30+00:00 https://www.trinitydelta.org/start-of-china-phase-i-of-hmpl-295-in-advanced-solid-tumours/ 2021-07-13T10:21:30+00:00 https://www.trinitydelta.org/full-exercise-of-over-allotment-option/ 2021-07-13T10:22:34+00:00 https://www.trinitydelta.org/25m-milestone-on-first-china-sale-of-orpathys/ 2021-07-13T10:24:43+00:00 https://www.trinitydelta.org/trading-update-for-the-year-ended-30-june-2021/ 2021-07-14T06:48:10+00:00 https://www.trinitydelta.org/diagnostics-achieves-iso-13485-certification/ 2021-07-14T12:28:36+00:00 https://www.trinitydelta.org/surufatinib-maa-submitted-and-validated-by-ema/ 2021-07-16T06:59:04+00:00 https://www.trinitydelta.org/med3000-fda-regulatory-and-commercial-update/ 2021-07-19T07:37:32+00:00 https://www.trinitydelta.org/phase-ii-dose-selection-of-rxc004/ 2021-07-27T09:43:22+00:00 https://www.trinitydelta.org/initiation-of-savolitinib-phase-ii-trial-in-met-amplified-gastric-cancer/ 2021-07-28T07:47:36+00:00 https://www.trinitydelta.org/contract-secured-for-bespoke-assay-development/ 2021-07-28T14:16:10+00:00 https://www.trinitydelta.org/h121-interims-and-business-update/ 2021-07-28T14:21:12+00:00 https://www.trinitydelta.org/professor-lindy-durrant-appointed-ceo/ 2021-07-30T07:02:03+00:00 https://www.trinitydelta.org/covidity-phase-1-cta-in-south-africa-approved/ 2021-07-30T07:03:03+00:00 https://www.trinitydelta.org/successful-primary-outcome-of-vlp-peanut-001/ 2021-08-03T06:40:50+00:00 https://www.trinitydelta.org/study-highlights-superior-performance-of-parsortix/ 2021-08-09T16:24:57+00:00 https://www.trinitydelta.org/update-on-affidx-lateral-flow-test/ 2021-08-09T16:26:05+00:00 https://www.trinitydelta.org/strategic-collaboration-with-epizyme-to-develop-and-commercialize-tazverik-in-greater-china/ 2021-08-09T16:28:21+00:00 https://www.trinitydelta.org/first-patient-dosed-in-ava6000-phase-1-trial/ 2021-08-11T10:10:33+00:00 https://www.trinitydelta.org/pharmajets-needle-free-systems-selected-for-covidity-001-study/ 2021-08-18T11:48:08+00:00 https://www.trinitydelta.org/modi-1-phase-i-ii-clinical-trial-application-approved-by-mhra/ 2021-08-31T13:13:21+00:00 https://www.trinitydelta.org/initiation-of-phase-ib-ii-trial-of-fruquintinib-tislelizumab-in-advanced-tnbc-or-advanced-ec/ 2021-08-31T13:26:56+00:00 https://www.trinitydelta.org/med3000-collaboration-for-commercialisation-in-key-latin-american-markets/ 2021-08-31T13:31:24+00:00 https://www.trinitydelta.org/milestone-payment-from-jazz-pharmaceuticals/ 2021-09-03T09:36:48+00:00 https://www.trinitydelta.org/initiation-of-sanovo-phase-iii-trial-of-orpathys-tagrisso-in-certain-nsclc-patients/ 2021-09-09T11:52:12+00:00 https://www.trinitydelta.org/first-day-of-dealings-on-aim/ 2021-09-14T06:37:14+00:00 https://www.trinitydelta.org/exclusive-formulation-study-collaboration-with-par-sterile-products/ 2021-09-14T06:37:41+00:00 https://www.trinitydelta.org/appointment-of-dr-lindsey-foulkes-as-coo/ 2021-09-14T06:38:15+00:00 https://www.trinitydelta.org/business-update/ 2021-09-14T06:42:16+00:00 https://www.trinitydelta.org/exclusive-formulation-collaboration-with-intas-pharmaceuticals/ 2021-09-14T06:42:40+00:00 https://www.trinitydelta.org/fda-clearance-of-ind-for-at247/ 2021-09-14T06:42:55+00:00 https://www.trinitydelta.org/secondary-endpoints-from-vlp-peanut-001/ 2021-09-14T09:02:31+00:00 https://www.trinitydelta.org/btd-in-china-for-hmpl-689-in-r-r-fl/ 2021-09-14T09:08:54+00:00 https://www.trinitydelta.org/first-patient-visit-in-med3000-confirmatory-study/ 2021-09-15T10:45:03+00:00 https://www.trinitydelta.org/rxc004-phase-i-monotherapy-data-to-be-presented-at-esmo-2021/ 2021-09-15T10:50:28+00:00 https://www.trinitydelta.org/positive-results-for-at278-phase-i-trial/ 2021-09-20T06:52:24+00:00 https://www.trinitydelta.org/encouraging-rxc004-phase-i-data-in-advanced-solid-tumours/ 2021-09-20T20:48:55+00:00 https://www.trinitydelta.org/h121-interim-results/ 2021-09-23T15:48:23+00:00 https://www.trinitydelta.org/preliminary-fy21-results/ 2021-09-23T15:49:31+00:00 https://www.trinitydelta.org/appointment-of-cso/ 2021-09-28T10:23:26+00:00 https://www.trinitydelta.org/parsortix-enables-gene-expression-analysis-in-mpca/ 2021-09-28T10:25:35+00:00 https://www.trinitydelta.org/study-shows-use-of-parsortix-to-assess-pd-l1/ 2021-09-28T10:26:22+00:00 https://www.trinitydelta.org/parsortix-demonstrates-ability-to-isolate-ctcs/ 2021-09-28T10:26:59+00:00 https://www.trinitydelta.org/med3000-collaboration-for-commercialisation-in-the-gulf-and-middle-east/ 2021-09-28T10:29:23+00:00 https://www.trinitydelta.org/start-of-japan-bridging-study-to-support-surufatinib-registration-for-advanced-nets/ 2021-09-28T10:33:55+00:00 https://www.trinitydelta.org/initiation-of-surtori-01-china-phase-iii-trial/ 2021-09-28T10:35:44+00:00 https://www.trinitydelta.org/interim-h121-results-3/ 2021-09-29T08:25:52+00:00 https://www.trinitydelta.org/interim-h121-results-4/ 2021-09-30T12:48:37+00:00 https://www.trinitydelta.org/development-milestone-in-lg-chem-partnership/ 2021-09-30T12:55:55+00:00 https://www.trinitydelta.org/interim-h121-results-5/ 2021-09-30T12:56:39+00:00 https://www.trinitydelta.org/positive-top-line-results-from-g309-exploratory-field-trial/ 2021-10-25T16:14:35+00:00 https://www.trinitydelta.org/polysaccharide-vaccine-patent-upheld/ 2021-10-25T16:19:18+00:00 https://www.trinitydelta.org/first-subject-dosed-in-south-africa-phase-i-covidity-trial/ 2021-10-25T16:47:26+00:00 https://www.trinitydelta.org/virtual-rd-day-and-new-clinical-data-for-rock2-inhibitor/ 2021-10-25T16:52:31+00:00 https://www.trinitydelta.org/results-for-the-year-ended-30-april-2021/ 2021-10-29T08:14:10+00:00 https://www.trinitydelta.org/exclusive-formulation-study-collaboration/ 2021-11-01T15:16:31+00:00 https://www.trinitydelta.org/closing-of-investment-of-non-core-otc-jv/ 2021-11-01T15:57:27+00:00 https://www.trinitydelta.org/initiation-of-eslim-01-china-phase-iii-trial-in-itp/ 2021-11-01T16:51:32+00:00 https://www.trinitydelta.org/initiation-of-sameta-global-phase-iii-trial/ 2021-11-01T16:52:31+00:00 https://www.trinitydelta.org/parsortix-system-showcased-at-ncri-festival/ 2021-11-19T14:17:04+00:00 https://www.trinitydelta.org/appointment-of-chief-medical-officer-2/ 2021-11-19T14:18:12+00:00 https://www.trinitydelta.org/appointment-of-non-exec-chair/ 2021-11-23T14:04:20+00:00 https://www.trinitydelta.org/first-patient-dosed-in-rxc004-phase-ii-trial-in-mcrc/ 2021-11-23T14:05:35+00:00 https://www.trinitydelta.org/first-patient-dosed-in-scib1-phase-ii-trial/ 2021-11-23T14:14:54+00:00 https://www.trinitydelta.org/ind-clearance-for-ava6000/ 2021-11-29T10:24:17+00:00 https://www.trinitydelta.org/parsortix-in-rna-analysis-of-ctcs-as-tool-in-nsclc/ 2021-12-14T13:46:37+00:00 https://www.trinitydelta.org/exclusive-collaboration-with-global-technology-leader/ 2021-12-14T14:27:03+00:00 https://www.trinitydelta.org/partnership-with-caris-life-sciences/ 2021-12-14T14:48:25+00:00 https://www.trinitydelta.org/redx-to-receive-10m-milestone-from-jazz/ 2021-12-14T14:57:33+00:00 https://www.trinitydelta.org/continued-inclusion-of-elunate-and-addition-of-sulanda-to-china-nrdl/ 2021-12-15T14:24:21+00:00 https://www.trinitydelta.org/completion-of-enrolment-in-global-fresco-2-phase-iii-of-fruquintinib-in-mcrc/ 2021-12-15T14:26:16+00:00 https://www.trinitydelta.org/initiation-of-sachi-china-phase-iii-trial/ 2021-12-15T14:26:52+00:00 https://www.trinitydelta.org/highlighted-surufatinib-and-toripalimab-combination-clinical-data-at-esmo-immuno-oncology-2021/ 2021-12-15T14:29:34+00:00 https://www.trinitydelta.org/highlighted-hmpl-523-clinical-data-at-ash-2021/ 2021-12-15T14:33:03+00:00 https://www.trinitydelta.org/us-regulatory-and-commercial-update-for-med3000/ 2021-12-20T11:11:41+00:00 https://www.trinitydelta.org/affidx-lft-receives-ce-mark-for-consumer-self-testing/ 2021-12-22T08:06:01+00:00 https://www.trinitydelta.org/affidx-lft-detects-the-omicron-variant/ 2021-12-22T08:06:43+00:00 https://www.trinitydelta.org/redx-to-receive-9m-milestone-from-astrazeneca/ 2021-12-23T09:44:39+00:00 https://www.trinitydelta.org/update-on-affidx-and-detection-of-omicron-variant/ 2022-01-10T16:51:15+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-of-btk-inhibitor-hmpl-760-in-b-cell-nhl/ 2022-01-10T16:52:43+00:00 https://www.trinitydelta.org/insight-into-drug-resistance-in-nsclc/ 2022-01-10T16:54:50+00:00 https://www.trinitydelta.org/update-on-lab-accreditation-and-ovarian-study/ 2022-01-13T09:28:34+00:00 https://www.trinitydelta.org/h122-trading-update-notice-of-results/ 2022-01-13T09:31:34+00:00 https://www.trinitydelta.org/concordance-of-parsortix-with-tissue-biopsy/ 2022-01-20T09:24:49+00:00 https://www.trinitydelta.org/second-precision-pro-drug-candidate-selected/ 2022-01-20T09:31:27+00:00 https://www.trinitydelta.org/fda-clearance-of-ind-application-for-vlp-peanut/ 2022-01-27T09:38:39+00:00 https://www.trinitydelta.org/potential-in-immunotherapy-treatment-selection/ 2022-01-27T09:39:50+00:00 https://www.trinitydelta.org/btd-in-china-for-hmpl-523-in-primary-itp/ 2022-01-27T09:44:53+00:00 https://www.trinitydelta.org/fruquintinib-clinical-data-at-2022-asco-gi-cancers-symposium/ 2022-01-27T09:46:50+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-of-hmpl-653-in-solid-tumours-and-tgct/ 2022-01-27T09:48:11+00:00 https://www.trinitydelta.org/fy21-results-operational-update/ 2022-01-27T09:57:42+00:00 https://www.trinitydelta.org/interim-results-to-31-october-2021/ 2022-01-27T09:59:40+00:00 https://www.trinitydelta.org/update-on-covidity-phase-i-trial/ 2022-02-08T16:00:56+00:00 https://www.trinitydelta.org/start-of-china-phase-ib-ii-start-of-hmpl-453-in-combination-with-chemo-or-toripalimab-for-advanced-solid-tumours/ 2022-02-08T16:25:32+00:00 https://www.trinitydelta.org/dose-escalation-in-ava6000-phase-i-study/ 2022-02-08T17:03:36+00:00 https://www.trinitydelta.org/new-credit-facility-secured/ 2022-02-08T17:20:24+00:00 https://www.trinitydelta.org/new-data-at-aaaai-2022-meeting/ 2022-03-03T09:56:07+00:00 https://www.trinitydelta.org/h122-interim-results/ 2022-03-03T09:56:52+00:00 https://www.trinitydelta.org/fy21-results-and-business-update/ 2022-03-04T14:21:50+00:00 https://www.trinitydelta.org/retirement-of-ceo-and-appointment-of-new-ceo/ 2022-03-04T14:36:55+00:00 https://www.trinitydelta.org/update-on-laboratory-accreditation/ 2022-03-15T13:47:02+00:00 https://www.trinitydelta.org/vimian-acquires-avactas-animal-health-division/ 2022-03-18T08:58:16+00:00 https://www.trinitydelta.org/scancell-progresses-its-new-anti-glycan-mab/ 2022-03-18T09:00:12+00:00 https://www.trinitydelta.org/encouraging-rxc007-phase-i-safety-data/ 2022-03-18T09:02:34+00:00 https://www.trinitydelta.org/15m-astrazeneca-milestone-on-savolitinib-global-phase-iii-start/ 2022-03-18T11:47:12+00:00 https://www.trinitydelta.org/update-on-status-under-hfcaa/ 2022-03-18T11:48:08+00:00 https://www.trinitydelta.org/grant-of-key-us-patent/ 2022-03-23T12:08:40+00:00 https://www.trinitydelta.org/collaboration-with-menarini-korea/ 2022-03-23T12:18:36+00:00 https://www.trinitydelta.org/identifying-therapeutic-targets-in-tnbc-patients/ 2022-04-05T12:26:57+00:00 https://www.trinitydelta.org/rapid-information-on-patient-response-to-therapies/ 2022-04-05T12:27:54+00:00 https://www.trinitydelta.org/identifying-drug-targets-in-cancer-metastasis/ 2022-04-05T12:29:00+00:00 https://www.trinitydelta.org/ava6000-preclinical-data-to-be-presented-at-aacr/ 2022-04-06T08:22:38+00:00 https://www.trinitydelta.org/preliminary-fy21-results-2/ 2022-04-06T08:24:40+00:00 https://www.trinitydelta.org/update-on-covidity-trial/ 2022-04-06T10:33:23+00:00 https://www.trinitydelta.org/rxc008-nominated-as-gi-rock-clinical-development-candidate/ 2022-04-06T10:34:15+00:00 https://www.trinitydelta.org/collaboration-with-garvan-institute-of-medical-research/ 2022-04-06T10:35:21+00:00 https://www.trinitydelta.org/affyxell-jv-partners-with-biocytogen-and-kntsc/ 2022-04-12T10:14:10+00:00 https://www.trinitydelta.org/2021-annual-report-and-notice-of-agm/ 2022-04-12T10:19:45+00:00 https://www.trinitydelta.org/update-on-status-under-hfcaa-3/ 2022-04-12T10:21:18+00:00 https://www.trinitydelta.org/rxc004-preclinical-data-presented-at-aacr/ 2022-04-12T10:24:43+00:00 https://www.trinitydelta.org/affyxell-jv-milestone-and-increased-equity-stake/ 2022-04-13T08:14:22+00:00 https://www.trinitydelta.org/parsortix-poster-presented-at-aacr/ 2022-04-14T07:47:51+00:00 https://www.trinitydelta.org/business-update-2/ 2022-04-14T08:05:45+00:00 https://www.trinitydelta.org/us-phase-i-trial-of-at247-starts/ 2022-04-14T08:06:38+00:00 https://www.trinitydelta.org/update-on-agreement-with-hikma/ 2022-04-14T08:07:50+00:00 https://www.trinitydelta.org/grant-of-key-canadian-patent/ 2022-04-14T08:08:47+00:00 https://www.trinitydelta.org/ava6000-poster-presented-at-aacr/ 2022-04-14T08:11:49+00:00 https://www.trinitydelta.org/modi-1-phase-1-2-trial-open-for-recruitment/ 2022-04-14T08:15:44+00:00 https://www.trinitydelta.org/data-at-wao-bsaci/ 2022-04-25T06:17:26+00:00 https://www.trinitydelta.org/final-fy21-results/ 2022-04-25T06:20:20+00:00 https://www.trinitydelta.org/fy21-results/ 2022-04-26T09:31:46+00:00 https://www.trinitydelta.org/fy21-results-2/ 2022-04-28T10:56:30+00:00 https://www.trinitydelta.org/at278-phase-i-data-at-attd/ 2022-04-29T08:52:07+00:00 https://www.trinitydelta.org/at278-phase-i-data-presentation-at-attd/ 2022-04-29T08:52:43+00:00 https://www.trinitydelta.org/rxc004-data-to-be-presented-at-asco/ 2022-04-29T08:55:45+00:00 https://www.trinitydelta.org/crl-for-surufatinib-from-us-fda/ 2022-05-06T08:18:59+00:00 https://www.trinitydelta.org/launch-of-placing-via-accelerated-book-build/ 2022-05-19T08:46:28+00:00 https://www.trinitydelta.org/result-of-accelerated-book-build/ 2022-05-19T12:57:40+00:00 https://www.trinitydelta.org/prostate-cancer-uk-funds-new-study/ 2022-05-20T08:39:14+00:00 https://www.trinitydelta.org/london-therapeutics-hq-established/ 2022-05-20T08:42:01+00:00 https://www.trinitydelta.org/affyxell-expands-partnership-with-genscript-probio/ 2022-05-20T08:42:55+00:00 https://www.trinitydelta.org/med3000-collaboration-in-eea-uk-switzerland/ 2022-05-23T06:19:22+00:00 https://www.trinitydelta.org/fda-clearance-for-parsortix/ 2022-05-25T13:01:12+00:00 https://www.trinitydelta.org/cfo-to-step-down/ 2022-05-27T14:53:11+00:00 https://www.trinitydelta.org/molecular-characterisation-of-ctcs/ 2022-05-27T15:10:11+00:00 https://www.trinitydelta.org/arecor-to-host-diabetes-kol-webinar/ 2022-05-27T15:12:16+00:00 https://www.trinitydelta.org/poster-on-rxc004-at-asco-2022/ 2022-05-30T13:14:25+00:00 https://www.trinitydelta.org/partnership-with-major-us-urology-group/ 2022-05-30T13:15:31+00:00 https://www.trinitydelta.org/tazverik-approved-in-hainan-pilot-zone-in-china/ 2022-06-10T08:48:20+00:00 https://www.trinitydelta.org/first-patient-dosed-in-modi-1-phase-1/ 2022-06-13T08:42:31+00:00 https://www.trinitydelta.org/potential-role-of-invasive-cellular-protrusions/ 2022-06-15T07:27:14+00:00 https://www.trinitydelta.org/phase-2-scib1-trial-expanded/ 2022-06-15T07:29:57+00:00 https://www.trinitydelta.org/pan-raf-inhibitor-to-enter-clinic/ 2022-06-15T07:31:16+00:00 https://www.trinitydelta.org/collaboration-with-top-5-global-pharma-company/ 2022-06-16T08:28:21+00:00 https://www.trinitydelta.org/predicting-immunotherapy-response-in-sclc/ 2022-06-17T08:47:55+00:00 https://www.trinitydelta.org/repeat-pharma-services-business/ 2022-06-22T07:55:20+00:00 https://www.trinitydelta.org/h122-interim-results-2/ 2022-06-24T12:46:07+00:00 https://www.trinitydelta.org/second-dose-escalation-in-ava6000-phase-i/ 2022-06-30T08:08:19+00:00 https://www.trinitydelta.org/lg-chem-licence-renewal-triggers-payment/ 2022-06-30T08:09:24+00:00 https://www.trinitydelta.org/data-at-eaaci-2022/ 2022-07-01T13:57:56+00:00 https://www.trinitydelta.org/breast-cancer-spread-accelerates-during-sleep/ 2022-07-01T14:00:49+00:00 https://www.trinitydelta.org/preclinical-data-at-ecm-2022/ 2022-07-01T14:03:48+00:00 https://www.trinitydelta.org/scancell-to-produce-tcb-antibodies/ 2022-07-01T14:06:18+00:00 https://www.trinitydelta.org/data-to-be-presented-at-easd-2022/ 2022-07-08T13:57:12+00:00 https://www.trinitydelta.org/first-participants-in-img-007-phase-i-trial/ 2022-07-08T13:59:48+00:00 https://www.trinitydelta.org/trading-update-7/ 2022-07-15T13:24:19+00:00 https://www.trinitydelta.org/proposed-placing/ 2022-07-15T13:29:14+00:00 https://www.trinitydelta.org/results-of-capital-raise/ 2022-07-15T13:30:13+00:00 https://www.trinitydelta.org/business-update-3/ 2022-07-15T13:31:51+00:00 https://www.trinitydelta.org/first-savannah-phase-ii-data/ 2022-07-15T13:35:44+00:00 https://www.trinitydelta.org/hmpl-a83-phase-i-starts/ 2022-07-15T13:37:20+00:00 https://www.trinitydelta.org/parsortix-enables-cancer-dna-analysis-in-nsclc/ 2022-07-22T09:02:54+00:00 https://www.trinitydelta.org/affyxell-completes-funding-round/ 2022-07-22T09:05:58+00:00 https://www.trinitydelta.org/novel-insights-into-metastasis-in-nsclc/ 2022-07-29T08:12:12+00:00 https://www.trinitydelta.org/proposed-acquisition-of-tetris-pharma-ltd/ 2022-08-01T08:15:17+00:00 https://www.trinitydelta.org/result-of-placing/ 2022-08-04T16:20:59+00:00 https://www.trinitydelta.org/tazemetostat-china-bridging-study-in-r-r-fl-starts/ 2022-08-04T16:23:58+00:00 https://www.trinitydelta.org/h122-interim-results-business-update/ 2022-08-04T16:24:58+00:00 https://www.trinitydelta.org/fresco-2-meets-primary-endpoint-in-mcrc/ 2022-08-08T10:49:31+00:00 https://www.trinitydelta.org/savannah-shows-49-orr-in-high-met-lung-cancer/ 2022-08-08T10:53:29+00:00 https://www.trinitydelta.org/eu-patents-for-biosimilar-humira-formulations/ 2022-08-12T08:08:01+00:00 https://www.trinitydelta.org/first-participant-in-img-004-phase-i-trial/ 2022-08-12T08:10:16+00:00 https://www.trinitydelta.org/first-patient-dosed-in-cohort-2-of-the-modify-phase-i-clinical-trial/ 2022-08-16T14:54:11+00:00 https://www.trinitydelta.org/fruquintinib-fresco-2-data-to-be-presented-at-esmo/ 2022-08-26T11:15:43+00:00 https://www.trinitydelta.org/highly-positive-fm71-phase-iii-data/ 2022-08-31T06:16:30+00:00 https://www.trinitydelta.org/preclinical-rxc007-data-at-ers-2022/ 2022-08-31T07:41:05+00:00 https://www.trinitydelta.org/ava6000-phase-i-moves-to-fourth-cohort/ 2022-09-02T08:04:33+00:00 https://www.trinitydelta.org/h122-interim-results-3/ 2022-09-08T06:35:01+00:00 https://www.trinitydelta.org/us-orphan-drug-designation-for-ava6000/ 2022-09-09T14:07:28+00:00 https://www.trinitydelta.org/fresco-2-data-summary/ 2022-09-09T14:10:12+00:00 https://www.trinitydelta.org/novel-assay-predicts-malignancy-in-pelvic-mass/ 2022-09-16T15:33:04+00:00 https://www.trinitydelta.org/poster-presented-at-ascp-meeting/ 2022-09-16T15:33:46+00:00 https://www.trinitydelta.org/interim-h122-results/ 2022-09-16T15:35:31+00:00 https://www.trinitydelta.org/at278-phase-i-data-presented-at-easd-2022/ 2022-09-21T16:39:22+00:00 https://www.trinitydelta.org/preclinical-data-at-euromabnet/ 2022-09-23T10:22:04+00:00 https://www.trinitydelta.org/interim-h122-results-2/ 2022-09-29T09:20:54+00:00 https://www.trinitydelta.org/preliminary-fy22-results/ 2022-09-29T09:22:15+00:00 https://www.trinitydelta.org/interim-h122-results-3/ 2022-09-29T09:32:51+00:00 https://www.trinitydelta.org/positive-headline-results-from-ovarian-study/ 2022-09-29T09:33:34+00:00 https://www.trinitydelta.org/subscription-and-debt-financing/ 2022-09-30T07:36:39+00:00 https://www.trinitydelta.org/application-to-the-us-fda-for-med3000/ 2022-10-04T09:49:31+00:00 https://www.trinitydelta.org/uk-manufacturing-update/ 2022-10-04T09:50:38+00:00 https://www.trinitydelta.org/preclinical-and-phase-i-safety-data-for-rxc007-at-iclaf-2022/ 2022-10-05T07:17:40+00:00 https://www.trinitydelta.org/initiation-of-china-phase-ii-iii-of-sovleplenib-for-waiha/ 2022-10-11T07:07:21+00:00 https://www.trinitydelta.org/first-patient-dosed-in-phase-iia-rxc007-ipf-trial/ 2022-10-11T07:09:38+00:00 https://www.trinitydelta.org/headline-results-from-phase-i-trial-of-at247/ 2022-10-11T07:12:31+00:00 https://www.trinitydelta.org/first-regional-distribution-agreement/ 2022-10-14T08:07:24+00:00 https://www.trinitydelta.org/change-of-nomad/ 2022-10-14T08:10:48+00:00 https://www.trinitydelta.org/streamlining-of-operations-to-increase-cash-runway/ 2022-10-18T07:33:59+00:00 https://www.trinitydelta.org/proposed-acquisition-of-launch-diagnostics/ 2022-10-18T08:36:41+00:00 https://www.trinitydelta.org/proposed-placing-open-offer-and-issue-of-convertible-bonds/ 2022-10-18T08:37:38+00:00 https://www.trinitydelta.org/result-of-placing-2/ 2022-10-18T11:03:13+00:00 https://www.trinitydelta.org/result-of-gm/ 2022-10-21T08:36:54+00:00 https://www.trinitydelta.org/commercial-licence-agreement-with-genmab/ 2022-10-25T06:50:29+00:00 https://www.trinitydelta.org/directorate-changes/ 2022-10-26T07:17:49+00:00 https://www.trinitydelta.org/uk-manufacturing-to-resume-in-mid-november/ 2022-10-28T06:35:12+00:00 https://www.trinitydelta.org/fy22-results-for-year-ended-30-april-2022/ 2022-10-28T07:20:01+00:00 https://www.trinitydelta.org/parsortix-poster-at-islb-meeting/ 2022-10-31T15:01:21+00:00 https://www.trinitydelta.org/avacta-to-present-at-theranostics-fap-summit/ 2022-10-31T15:03:02+00:00 https://www.trinitydelta.org/initiation-of-china-phase-ii-iii-of-fruquintinib-sintilimab-for-advanced-rcc/ 2022-10-31T15:05:25+00:00 https://www.trinitydelta.org/poster-at-asn-kidney-week/ 2022-10-31T15:07:12+00:00 https://www.trinitydelta.org/first-patient-dosed-in-expansion-phase-of-modify/ 2022-10-31T15:08:12+00:00 https://www.trinitydelta.org/multiple-downstream-analysis-techniques-for-ctcs/ 2022-11-07T14:06:19+00:00 https://www.trinitydelta.org/tetris-pharma-launches-ogluo-in-germany/ 2022-11-07T14:08:13+00:00 https://www.trinitydelta.org/poster-on-phase-i-rxc004-combination-arm-data-at-sitc/ 2022-11-07T14:24:08+00:00 https://www.trinitydelta.org/poster-on-rxc007-potential-in-fibrotic-diseases-at-afdd/ 2022-11-07T14:26:11+00:00 https://www.trinitydelta.org/vaccitech-technology-licenced-to-advance-modi-2/ 2022-11-07T14:58:32+00:00 https://www.trinitydelta.org/exclusive-specialty-hospital-formulation-collaboration/ 2022-11-10T10:13:13+00:00 https://www.trinitydelta.org/rxc004-phase-ii-combination-arms-to-open-enrolment/ 2022-11-11T08:48:07+00:00 https://www.trinitydelta.org/strategy-to-focus-on-late-stage-pipeline-regulatory-approvals/ 2022-11-15T14:15:20+00:00 https://www.trinitydelta.org/top-line-data-from-frutiga-china-phase-iii-in-2l-gastric-cancer/ 2022-11-15T14:16:58+00:00 https://www.trinitydelta.org/appointment-of-interim-cfo/ 2022-11-21T13:37:32+00:00 https://www.trinitydelta.org/result-of-the-open-offer/ 2022-11-21T13:40:11+00:00 https://www.trinitydelta.org/poster-to-be-presented-at-ibd-nordic-conference/ 2022-11-21T13:42:48+00:00 https://www.trinitydelta.org/insulin-product-patents-granted-in-japan-and-south-korea/ 2022-11-22T09:25:34+00:00 https://www.trinitydelta.org/second-at278-trial-to-commence-in-tyep-ii-diabetes/ 2022-11-22T09:28:24+00:00 https://www.trinitydelta.org/key-updates-on-grass-mata-mpl-and-vlp-peanut/ 2022-12-08T08:49:30+00:00 https://www.trinitydelta.org/milestone-year-for-med3000/ 2022-12-13T07:49:58+00:00 https://www.trinitydelta.org/two-parsortix-posters-presented-at-sabcs/ 2022-12-16T10:29:29+00:00 https://www.trinitydelta.org/tetris-pharma-service-agreement-with-syneos-health/ 2022-12-16T10:31:35+00:00 https://www.trinitydelta.org/clinical-trial-agreement-with-msd/ 2022-12-16T10:33:37+00:00 https://www.trinitydelta.org/initiation-of-fruquintinib-us-rolling-nda-submission-in-mcrc/ 2022-12-19T10:40:50+00:00 https://www.trinitydelta.org/avacta-to-host-therapeutics-division-science-day/ 2022-12-19T10:42:36+00:00 https://www.trinitydelta.org/fy22-results/ 2022-12-20T07:28:09+00:00 https://www.trinitydelta.org/fy22-annual-report-and-accounts-delayed/ 2022-12-29T14:03:38+00:00 https://www.trinitydelta.org/completion-of-enrolment-of-china-phase-iii-eslim-01-trial-of-sovleplenib-in-primary-itp/ 2023-01-03T14:57:10+00:00 https://www.trinitydelta.org/business-update-4/ 2023-01-05T07:32:44+00:00 https://www.trinitydelta.org/tetris-pharma-launches-ogluo-in-austria/ 2023-01-06T11:06:54+00:00 https://www.trinitydelta.org/at307-transfers-to-hikma/ 2023-01-12T10:37:59+00:00 https://www.trinitydelta.org/successful-completion-of-fourth-ava6000-dose-escalation/ 2023-01-17T08:28:16+00:00 https://www.trinitydelta.org/nhsa-agreement-for-orpathys-inclusion-on-china-nrdl/ 2023-01-18T15:43:28+00:00 https://www.trinitydelta.org/business-update-5/ 2023-01-19T17:32:56+00:00 https://www.trinitydelta.org/h123-trading-update/ 2023-01-20T09:09:21+00:00 https://www.trinitydelta.org/takeda-licences-fruquintinib-ex-china-development-and-commercial-rights/ 2023-01-23T16:09:25+00:00 https://www.trinitydelta.org/h123-interim-results/ 2023-01-25T08:26:37+00:00 https://www.trinitydelta.org/pre-launch-of-med3000-ahead-of-h123-launch/ 2023-01-26T11:22:11+00:00 https://www.trinitydelta.org/dr-jean-michel-cossery-appointed-chairman/ 2023-02-01T07:50:18+00:00 https://www.trinitydelta.org/at278-data-published-in-diabetes-care/ 2023-02-03T10:56:26+00:00 https://www.trinitydelta.org/progress-update-on-rxc007-clinical-programme/ 2023-02-09T08:13:19+00:00 https://www.trinitydelta.org/positive-response-in-covidity-trial/ 2023-02-13T08:04:07+00:00 https://www.trinitydelta.org/additional-formulation-agreement-with-top-5-global-pharma-partner/ 2023-02-14T08:24:03+00:00 https://www.trinitydelta.org/encouraging-early-efficacy-data-from-modify-trial/ 2023-02-21T07:33:50+00:00 https://www.trinitydelta.org/recommended-business-combination-with-jounce-therapeutics/ 2023-02-23T10:44:57+00:00 https://www.trinitydelta.org/completion-of-enrolment-in-amidizalisib-china-phase-ii-registration-trial-in-fl/ 2023-02-27T13:03:39+00:00 https://www.trinitydelta.org/fy22-results-2/ 2023-02-28T14:36:30+00:00 https://www.trinitydelta.org/rxc004-topline-data-from-a-phase-ii-monotherapy-module/ 2023-03-08T09:42:37+00:00 https://www.trinitydelta.org/med3000-commercial-and-us-regulatory-update/ 2023-03-14T12:33:45+00:00 https://www.trinitydelta.org/closing-of-fruquintinib-licence-to-takeda-outside-china/ 2023-03-14T16:04:25+00:00 https://www.trinitydelta.org/statement-re-jounce-therapeutics-press-release/ 2023-03-15T16:42:45+00:00 https://www.trinitydelta.org/first-patient-dosed-in-at278-trial/ 2023-03-24T13:16:52+00:00 https://www.trinitydelta.org/avacta-therapeutics-division-science-day/ 2023-03-24T13:19:57+00:00 https://www.trinitydelta.org/med3000-fm71-data-at-essm/ 2023-03-24T13:23:04+00:00 https://www.trinitydelta.org/patients-dosed-in-vlp-peanut-protect-trial/ 2023-03-27T09:42:11+00:00 https://www.trinitydelta.org/ava3996-preclinical-data-poster-presentation-at-aacr/ 2023-03-27T10:01:31+00:00 https://www.trinitydelta.org/completion-of-nda-rolling-submission-to-fda-for-fruquintinib-in-refractory-mcrc/ 2023-03-31T10:21:29+00:00 https://www.trinitydelta.org/statement-following-jounce-announcement/ 2023-04-03T15:19:30+00:00 https://www.trinitydelta.org/proposed-business-combination-formally-lapsed/ 2023-04-03T15:20:31+00:00 https://www.trinitydelta.org/fy22-results-4/ 2023-04-05T06:42:18+00:00 https://www.trinitydelta.org/first-patient-dosed-in-fifth-cohort-of-ava6000-phase-i-study/ 2023-04-05T07:20:27+00:00 https://www.trinitydelta.org/appointment-of-chief-business-officer/ 2023-04-05T07:22:00+00:00 https://www.trinitydelta.org/trading-and-business-update/ 2023-04-06T13:49:05+00:00 https://www.trinitydelta.org/40-75-million-facility-with-equity-financing/ 2023-04-06T13:50:01+00:00 https://www.trinitydelta.org/statement-regarding-possible-mandatory-cash-offer/ 2023-04-06T13:51:00+00:00 https://www.trinitydelta.org/first-us-clinical-investigator-ava6000-sites-opened/ 2023-04-06T13:59:08+00:00 https://www.trinitydelta.org/skin-prick-testing-completes-in-protect-trial/ 2023-04-19T06:55:17+00:00 https://www.trinitydelta.org/pharma-services-contract-with-crescendo-biologics/ 2023-04-19T06:57:13+00:00 https://www.trinitydelta.org/parsortix-poster-presented-at-aacr-2023/ 2023-04-19T06:58:18+00:00 https://www.trinitydelta.org/ava3996-data-poster-presented-at-aacr/ 2023-04-19T07:01:36+00:00 https://www.trinitydelta.org/eroxon-med3000-uk-launch/ 2023-04-19T07:03:05+00:00 https://www.trinitydelta.org/china-registration-phases-initiate-for-hmpl-453-and-savolitinib/ 2023-04-19T07:07:12+00:00 https://www.trinitydelta.org/aacr-2023-presentations/ 2023-04-19T07:08:34+00:00 https://www.trinitydelta.org/fruquintinib-nda-accepted-in-china-for-2l-gastric-cancer/ 2023-04-19T07:09:47+00:00 https://www.trinitydelta.org/modify-phase-1-2-poster-at-aacr-2023/ 2023-04-19T07:13:36+00:00 https://www.trinitydelta.org/partnership-with-bioview/ 2023-04-19T13:19:14+00:00 https://www.trinitydelta.org/unaudited-preliminary-fy22-results/ 2023-04-20T06:47:44+00:00 https://www.trinitydelta.org/fy22-results-5/ 2023-04-21T06:07:48+00:00 https://www.trinitydelta.org/fy22-results-6/ 2023-04-25T07:49:06+00:00 https://www.trinitydelta.org/first-patient-dosed-in-the-us-in-ava6000-phase-i-study/ 2023-04-27T12:39:51+00:00 https://www.trinitydelta.org/presentation-at-keystone-symposia/ 2023-05-11T06:34:39+00:00 https://www.trinitydelta.org/rxc007-preclinical-data/ 2023-05-11T06:35:25+00:00 https://www.trinitydelta.org/interim-h123-results-for-the-six-months-ended-31-march/ 2023-05-17T06:36:49+00:00 https://www.trinitydelta.org/board-change-appointment-of-new-chairman/ 2023-05-23T10:07:05+00:00 https://www.trinitydelta.org/pharma-services-contract-with-artios-pharma/ 2023-05-26T10:10:13+00:00 https://www.trinitydelta.org/tetris-pharma-launches-ogluo-in-denmark-norway/ 2023-05-26T10:12:01+00:00 https://www.trinitydelta.org/us-patent-grant-protecting-proprietary-mab-formulations/ 2023-05-26T10:12:37+00:00 https://www.trinitydelta.org/data-presentations-at-asco-2023/ 2023-05-26T10:16:21+00:00 https://www.trinitydelta.org/fruquintinib-granted-us-priority-review/ 2023-05-26T10:17:28+00:00 https://www.trinitydelta.org/aquisition-of-coris-bioconcept/ 2023-06-01T08:49:48+00:00 https://www.trinitydelta.org/senior-management-appointments/ 2023-06-05T09:39:07+00:00 https://www.trinitydelta.org/second-milestone-in-affyxell-jv/ 2023-06-05T09:40:04+00:00 https://www.trinitydelta.org/med3000-us-fda-approval-for-otc-sale/ 2023-06-12T08:10:30+00:00 https://www.trinitydelta.org/presentations-at-eha-and-icml-2023-meetings/ 2023-06-16T14:06:52+00:00 https://www.trinitydelta.org/fruquintinib-maa-accepted-by-ema-for-mcrc/ 2023-06-16T14:08:34+00:00 https://www.trinitydelta.org/phase-iii-fresco-2-results-published-in-the-lancet/ 2023-06-16T14:09:31+00:00 https://www.trinitydelta.org/publication-of-2022-annual-report-and-accounts/ 2023-06-19T13:41:58+00:00 https://www.trinitydelta.org/interim-h123-results-and-lifting-of-suspension-in-trading/ 2023-06-19T13:43:16+00:00 https://www.trinitydelta.org/modify-phase-i-ii-data-at-asco-2023/ 2023-06-19T14:18:25+00:00 https://www.trinitydelta.org/completion-of-fifth-dose-escalation-of-ava6000/ 2023-06-21T08:02:10+00:00 https://www.trinitydelta.org/agm-statement/ 2023-06-22T06:45:29+00:00 https://www.trinitydelta.org/positive-at247-data-presented-at-ada/ 2023-07-05T13:10:42+00:00 https://www.trinitydelta.org/key-patents-granted-in-europe-china/ 2023-07-05T13:11:37+00:00 https://www.trinitydelta.org/additional-agreement-with-leading-biopharma/ 2023-07-05T13:12:25+00:00 https://www.trinitydelta.org/appointment-of-cfo-2/ 2023-07-11T10:36:24+00:00 https://www.trinitydelta.org/data-at-eaaci/ 2023-07-11T10:38:23+00:00 https://www.trinitydelta.org/start-of-hmpl-415-phase-i-study-in-china/ 2023-07-11T10:42:56+00:00 https://www.trinitydelta.org/extension-to-cln/ 2023-07-11T10:45:05+00:00 https://www.trinitydelta.org/pipeline-strategy-and-business-update/ 2023-07-11T10:46:21+00:00 https://www.trinitydelta.org/us-commercialisation-agreement-with-haleon/ 2023-07-17T06:43:08+00:00 https://www.trinitydelta.org/h123-business-update/ 2023-07-20T09:12:37+00:00 https://www.trinitydelta.org/china-btd-for-fruquintinib-combo-in-advanced-endometrial-cancer/ 2023-07-20T09:18:08+00:00 https://www.trinitydelta.org/modi-1-trial-open-for-expansion-in-cpi-combination/ 2023-07-31T16:55:45+00:00 https://www.trinitydelta.org/h123-interim-results-business-update/ 2023-07-31T16:57:00+00:00 https://www.trinitydelta.org/board-change-2/ 2023-08-04T11:20:16+00:00 https://www.trinitydelta.org/trading-update/ 2023-08-11T14:57:13+00:00 https://www.trinitydelta.org/med3000-approval-in-saudi-arabia/ 2023-08-11T14:59:12+00:00 https://www.trinitydelta.org/collaboration-with-top-10-global-pharma/ 2023-08-17T08:30:36+00:00 https://www.trinitydelta.org/sovleplenib-itp-phase-iii-met-primary-endpoint-in-china/ 2023-08-21T08:21:01+00:00 https://www.trinitydelta.org/zelasudil-rxc007-granted-fda-orphan-drug-designation/ 2023-08-21T08:25:03+00:00 https://www.trinitydelta.org/btd-granted-in-china-for-savolitinib-in-gastric-cancer/ 2023-09-01T13:45:49+00:00 https://www.trinitydelta.org/appointment-of-cfo-3/ 2023-09-01T13:49:47+00:00 https://www.trinitydelta.org/tetris-pharma-collaboration-with-goodlife/ 2023-09-04T10:38:02+00:00 https://www.trinitydelta.org/launch-of-portrait-flex-assay/ 2023-09-04T10:39:03+00:00 https://www.trinitydelta.org/interim-h123-results/ 2023-09-07T06:27:53+00:00 https://www.trinitydelta.org/at307-positive-fda-pre-ind-meeting/ 2023-09-07T12:17:03+00:00 https://www.trinitydelta.org/appointment-of-head-of-business-development/ 2023-09-07T12:18:25+00:00 https://www.trinitydelta.org/completion-of-enrollment-in-tazemetostat-china-bridging-study-in-r-r-fl/ 2023-09-12T10:41:10+00:00 https://www.trinitydelta.org/presentation-of-results-from-the-phase-iiib-trial-of-savolitinib-at-wclc-2023/ 2023-09-12T10:43:20+00:00 https://www.trinitydelta.org/interim-h123-results-2/ 2023-09-14T06:33:35+00:00 https://www.trinitydelta.org/interim-h123-results-3/ 2023-09-18T06:24:30+00:00 https://www.trinitydelta.org/positive-data-from-first-stage-of-scib1-phase-ii-scope-trial-in-advanced-melanoma/ 2023-09-19T06:16:31+00:00 https://www.trinitydelta.org/completion-of-ava6000-sixth-dose-escalation-and-clinical-update/ 2023-09-19T10:26:56+00:00 https://www.trinitydelta.org/satisfaction-of-fdi-clearance-conditions/ 2023-09-26T07:12:21+00:00 https://www.trinitydelta.org/phase-i-vlp-peanut-protect-trial-progress/ 2023-09-26T07:13:16+00:00 https://www.trinitydelta.org/unaudited-preliminary-fy23-results/ 2023-09-27T13:03:24+00:00 https://www.trinitydelta.org/publication-of-open-offer-circular/ 2023-09-27T13:06:17+00:00 https://www.trinitydelta.org/h123-interim-results-2/ 2023-09-28T07:59:36+00:00 https://www.trinitydelta.org/submission-of-fruquintinib-japan-nda-in-mcrc/ 2023-09-29T15:12:42+00:00 https://www.trinitydelta.org/progress-of-phase-i-clinical-study-of-at278/ 2023-10-02T07:23:43+00:00 https://www.trinitydelta.org/med3000-european-patent-granted-until-2040/ 2023-10-02T07:25:22+00:00 https://www.trinitydelta.org/result-of-open-offer-and-subscription/ 2023-10-13T08:31:11+00:00 https://www.trinitydelta.org/presentation-at-aacr-nci-eortc-conference/ 2023-10-13T08:34:20+00:00 https://www.trinitydelta.org/unconditional-mandatory-cash-offer/ 2023-10-17T16:09:54+00:00 https://www.trinitydelta.org/proposed-subscription-to-raise-c-14-1m/ 2023-10-18T06:33:42+00:00 https://www.trinitydelta.org/parsortix-showcased-at-actc/ 2023-10-18T06:36:01+00:00 https://www.trinitydelta.org/parsortix-outperforms-standard-for-dtc-harvest/ 2023-10-18T06:36:49+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-esmo-2023/ 2023-10-18T06:46:00+00:00 https://www.trinitydelta.org/presentation-at-world-vaccine-congress-europe/ 2023-10-18T06:48:10+00:00 https://www.trinitydelta.org/posting-of-offer-document/ 2023-10-19T07:58:09+00:00 https://www.trinitydelta.org/eroxon-launches-in-uae/ 2023-10-19T07:59:17+00:00 https://www.trinitydelta.org/results-for-the-year-ended-30-april-2023/ 2023-10-31T11:04:23+00:00 https://www.trinitydelta.org/preclinical-rxc009-data-to-be-presented-at-asn/ 2023-10-31T11:07:27+00:00 https://www.trinitydelta.org/eroxon-granted-marketing-authorisation-in-mexico/ 2023-10-31T11:44:22+00:00 https://www.trinitydelta.org/parsortix-supports-characterisation-of-ctcs-in-hnscc/ 2023-10-31T12:02:42+00:00 https://www.trinitydelta.org/update-on-funding/ 2023-11-07T11:12:33+00:00 https://www.trinitydelta.org/inhibrx-milestone-triggers-payment-to-arecor/ 2023-11-07T11:15:04+00:00 https://www.trinitydelta.org/futura-expands-partnership-with-m8-pharmaceuticals/ 2023-11-07T11:17:17+00:00 https://www.trinitydelta.org/presentation-of-preclinical-rxc009-data/ 2023-11-07T11:37:13+00:00 https://www.trinitydelta.org/presentation-of-data-from-first-stage-of-phase-ii-scope-trial-at-38th-annual-sitc-meeting/ 2023-11-07T11:40:09+00:00 https://www.trinitydelta.org/fda-approval-of-fruzaqla-fruquintinib-for-previously-treated-mcrc/ 2023-11-09T11:04:01+00:00 https://www.trinitydelta.org/launch-of-pd-l1-test-to-support-cancer-studies/ 2023-11-09T11:07:08+00:00 https://www.trinitydelta.org/trading-and-business-update-2/ 2023-11-09T11:07:51+00:00 https://www.trinitydelta.org/g306-grass-phase-iii-trial-meets-primary-endpoint/ 2023-11-16T17:16:17+00:00 https://www.trinitydelta.org/product-with-arestat-technology-launched-in-europe/ 2023-11-17T15:11:44+00:00 https://www.trinitydelta.org/arecor-continues-collaboration-with-lilly/ 2023-11-29T07:30:41+00:00 https://www.trinitydelta.org/update-on-scope-trial/ 2023-11-29T07:32:11+00:00 https://www.trinitydelta.org/upsized-placing-raises-10-7m/ 2023-12-01T07:21:49+00:00 https://www.trinitydelta.org/agreement-with-global-medical-products-company/ 2023-12-04T08:11:44+00:00 https://www.trinitydelta.org/shareholder-update-to-review-ava6000-phase-1a-data/ 2023-12-04T08:12:41+00:00 https://www.trinitydelta.org/launch-of-portrait-ctc-kit/ 2023-12-05T09:17:34+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-congresses/ 2023-12-08T08:33:32+00:00 https://www.trinitydelta.org/disposal-of-interest-in-consumer-products-businesses/ 2023-12-08T08:35:14+00:00 https://www.trinitydelta.org/parsortix-unlocks-opportunities-for-drug-discovery/ 2023-12-11T08:24:39+00:00 https://www.trinitydelta.org/update-on-funding-2/ 2023-12-11T08:25:53+00:00 https://www.trinitydelta.org/enrolment-complete-in-fruquintinib-sintilimab-phase-ii-iii-rcc-trial-in-china/ 2023-12-13T08:10:23+00:00 https://www.trinitydelta.org/elunate-and-sulanda-continued-inclusion-in-nrdl/ 2023-12-13T08:11:38+00:00 https://www.trinitydelta.org/g306-phase-iii-trial-meets-key-endpoints/ 2023-12-13T08:13:06+00:00 https://www.trinitydelta.org/ava6000-phase-1a-safety-study-data/ 2023-12-13T08:14:42+00:00 https://www.trinitydelta.org/fy23-results/ 2023-12-15T10:04:43+00:00 https://www.trinitydelta.org/fy23-annual-report-and-accounts-delayed/ 2023-12-15T15:09:09+00:00 https://www.trinitydelta.org/appointment-of-chief-business-officer-2/ 2023-12-19T08:20:11+00:00 https://www.trinitydelta.org/result-of-the-open-offer-2/ 2023-12-19T08:21:11+00:00 https://www.trinitydelta.org/contract-announcement-with-eisai-inc/ 2024-01-03T08:45:39+00:00 https://www.trinitydelta.org/amendment-to-existing-facility-agreement/ 2024-01-03T08:47:27+00:00 https://www.trinitydelta.org/appointment-of-svp-for-tetris-pharma-ltd/ 2024-01-03T08:52:37+00:00 https://www.trinitydelta.org/dna-sample-to-answer-molecular-solution/ 2024-01-05T11:25:50+00:00 https://www.trinitydelta.org/expansion-of-specialty-hospital-collaboration/ 2024-01-08T10:29:58+00:00 https://www.trinitydelta.org/grant-of-key-european-insulin-patent/ 2024-01-18T08:16:12+00:00 https://www.trinitydelta.org/futura-extends-collaboration-with-cooper-consumer-health/ 2024-01-18T08:18:41+00:00 https://www.trinitydelta.org/nda-acceptance-in-china-for-sovleplenib-for-itp/ 2024-01-18T08:21:18+00:00 https://www.trinitydelta.org/update-on-scope-trial-mhra-approves-third-cohort-with-iscib1/ 2024-01-18T08:25:03+00:00 https://www.trinitydelta.org/update-on-inbrx-101/ 2024-01-23T17:09:08+00:00 https://www.trinitydelta.org/potential-utility-in-precision-oncology/ 2024-01-26T12:18:32+00:00 https://www.trinitydelta.org/publication-of-annual-report-and-accounts-2023/ 2024-01-30T09:10:42+00:00 https://www.trinitydelta.org/h124-interim-results/ 2024-01-30T09:11:36+00:00 https://www.trinitydelta.org/elunate-fruquintinib-hong-kong-marketing-approval-for-treatment-of-mcrc/ 2024-01-30T09:13:30+00:00 https://www.trinitydelta.org/year-end-trading-update/ 2024-02-01T07:44:33+00:00 https://www.trinitydelta.org/inmagene-exercises-option-to-two-candidates/ 2024-02-02T13:49:41+00:00 https://www.trinitydelta.org/appointment-of-joint-corporate-broker/ 2024-02-06T09:46:46+00:00 https://www.trinitydelta.org/trading-update-2/ 2024-02-06T09:47:33+00:00 https://www.trinitydelta.org/jazz-pharmaceuticals-acquires-kras-programme/ 2024-02-07T07:16:49+00:00 https://www.trinitydelta.org/first-participant-dosed-in-rxc008-phase-i-trial/ 2024-02-28T07:18:00+00:00 https://www.trinitydelta.org/eroxon-to-be-available-on-prescription/ 2024-02-28T10:53:33+00:00 https://www.trinitydelta.org/phase-iii-fruquintinib-data-in-2l-gastric-cancer-presented-at-asco-plenary-series-session/ 2024-02-28T10:55:37+00:00 https://www.trinitydelta.org/statement-re-press-report/ 2024-02-28T10:57:02+00:00 https://www.trinitydelta.org/change-of-auditor/ 2024-02-28T10:58:19+00:00 https://www.trinitydelta.org/fy23-results-business-update/ 2024-02-28T17:38:07+00:00 https://www.trinitydelta.org/appointment-of-head-of-rd/ 2024-02-28T17:39:05+00:00 https://www.trinitydelta.org/proposed-fundraise-to-progress-therapeutics/ 2024-02-28T17:39:58+00:00 https://www.trinitydelta.org/proposed-rex-retail-offer/ 2024-02-28T17:40:40+00:00 https://www.trinitydelta.org/launch-of-ogluo-in-the-netherlands/ 2024-02-29T10:49:15+00:00 https://www.trinitydelta.org/result-of-placing-3/ 2024-03-06T08:28:15+00:00 https://www.trinitydelta.org/result-of-rex-retail-offer/ 2024-03-06T08:29:14+00:00 https://www.trinitydelta.org/ava6000-poster-at-aacr/ 2024-03-06T08:30:54+00:00 https://www.trinitydelta.org/redx-to-exhibit-three-posters-at-aacr/ 2024-03-06T08:32:23+00:00 https://www.trinitydelta.org/next-gen-immuno-oncology-conference-presentation/ 2024-03-08T11:41:44+00:00 https://www.trinitydelta.org/trx-biosciences-glp-1-research-collaboration/ 2024-03-13T08:50:02+00:00 https://www.trinitydelta.org/update-on-ava6000-phase-ia-clinical-trial-progress/ 2024-03-25T15:57:16+00:00 https://www.trinitydelta.org/initiation-of-registration-stage-of-sovleplenib-china-eslim-2-phase-ii-iii-trial-in-waiha/ 2024-03-25T16:00:35+00:00 https://www.trinitydelta.org/appointment-of-sath-nirmalananthan-to-the-board-of-directors/ 2024-03-25T16:02:44+00:00 https://www.trinitydelta.org/acceptance-of-china-snda-for-savolitinib-for-treatment-naive-and-previously-treated-met-ex14-nsclc/ 2024-03-28T09:12:00+00:00 https://www.trinitydelta.org/first-iscib1-patient-dosed/ 2024-03-28T09:14:12+00:00 https://www.trinitydelta.org/china-nda-acceptance-for-fruquintinib-sintilimab-for-advanced-endometrial-cancer/ 2024-04-03T06:58:26+00:00 https://www.trinitydelta.org/proposed-cancellation-of-admission-to-trading/ 2024-04-03T06:59:45+00:00 https://www.trinitydelta.org/scancell-to-present-at-aacr-2024/ 2024-04-03T07:01:16+00:00 https://www.trinitydelta.org/ava6000-abstract-release-by-aacr/ 2024-04-08T08:23:30+00:00 https://www.trinitydelta.org/data-to-be-presented-at-aacr-2024/ 2024-04-08T08:25:00+00:00 https://www.trinitydelta.org/fy23-results-2/ 2024-04-10T06:13:35+00:00 https://www.trinitydelta.org/aacr-data/ 2024-04-10T06:15:15+00:00 https://www.trinitydelta.org/board-change-cfo-to-step-down/ 2024-04-30T06:56:37+00:00 https://www.trinitydelta.org/board-change-christina-coughlin-appointed-ceo/ 2024-04-30T06:58:01+00:00 https://www.trinitydelta.org/fy23-results-3/ 2024-04-30T06:58:43+00:00 https://www.trinitydelta.org/arecor-and-medtronic-diabetes-collaboration/ 2024-05-09T06:22:02+00:00 https://www.trinitydelta.org/fy23-results-4/ 2024-05-16T06:17:47+00:00 https://www.trinitydelta.org/positive-chmp-opinion-for-fruquintinib-in-previously-treated-mcrc/ 2024-05-16T06:29:09+00:00 https://www.trinitydelta.org/surufatinib-camrelizumab-phase-ii-iii-in-pdac-initiated-with-hengrui/ 2024-05-16T06:33:31+00:00 https://www.trinitydelta.org/registrational-phase-iii-of-hmpl-306-in-r-raml-initiated-in-china/ 2024-05-16T06:35:17+00:00 https://www.trinitydelta.org/aim-cancellation/ 2024-05-16T06:37:30+00:00 https://www.trinitydelta.org/scancell-to-present-at-the-sachs-10th-annual-oncology-innovation-forum/ 2024-05-16T06:38:38+00:00 https://www.trinitydelta.org/positive-headline-results-for-at278/ 2024-05-20T07:51:37+00:00 https://www.trinitydelta.org/completion-of-first-2-weekly-cohort/ 2024-05-24T15:07:47+00:00 https://www.trinitydelta.org/sovleplenib-phase-iii-data-to-be-presented-at-eha2024/ 2024-05-24T15:11:04+00:00 https://www.trinitydelta.org/data-presentations-at-asco-2024/ 2024-05-24T15:13:56+00:00 https://www.trinitydelta.org/scancell-to-present-at-asco-2024/ 2024-05-24T15:15:13+00:00 https://www.trinitydelta.org/publication-of-phase-iii-frutiga-results-in-nature-medicine/ 2024-06-05T13:28:25+00:00 https://www.trinitydelta.org/redx-shares-now-trading-on-jp-jenkins/ 2024-06-05T13:30:20+00:00 https://www.trinitydelta.org/changes-to-board-composition/ 2024-06-05T13:31:30+00:00 https://www.trinitydelta.org/agreement-with-major-biotech/ 2024-06-12T07:39:56+00:00 https://www.trinitydelta.org/company-and-kol-webinar/ 2024-06-12T07:50:33+00:00 https://www.trinitydelta.org/trading-and-funding-update/ 2024-06-12T07:51:23+00:00 https://www.trinitydelta.org/initiation-of-china-phase-i-trial-of-menin-inhibitor-hmpl-506-in-hematological-malignancies/ 2024-06-24T19:57:41+00:00 https://www.trinitydelta.org/ppublication-of-phase-iii-eslim-01-results-in-the-lancet-haematology/ 2024-06-24T19:58:42+00:00 https://www.trinitydelta.org/european-commission-approval-for-fruzaqla-fruquintinib-received-by-takeda/ 2024-06-24T20:00:45+00:00 https://www.trinitydelta.org/save-the-date-rd-updates-on-july-9-2024/ 2024-06-24T20:01:56+00:00 https://www.trinitydelta.org/shaun-chilton-appointed-non-executive-chairman/ 2024-06-24T20:06:40+00:00 https://www.trinitydelta.org/agm-statement-2/ 2024-06-24T20:09:37+00:00 https://www.trinitydelta.org/rxc008-preclinical-data-in-oral-presentation-at-ecm-congress/ 2024-06-24T20:14:35+00:00 https://www.trinitydelta.org/zamaporvint-phase-ii-data-presentation-at-esmo-gi/ 2024-06-24T20:15:54+00:00 https://www.trinitydelta.org/agm-business-update/ 2024-07-05T09:27:51+00:00 https://www.trinitydelta.org/tazemetostat-china-nda-acceptance-with-priority-review-for-r-r-fl/ 2024-07-05T09:30:34+00:00 https://www.trinitydelta.org/encouraging-zamaporvint-phase-ii-data-at-esmo-gi/ 2024-07-05T09:32:17+00:00 https://www.trinitydelta.org/change-of-nomad-2/ 2024-07-05T09:33:34+00:00 https://www.trinitydelta.org/extension-of-convertible-loan-notes/ 2024-07-05T09:34:17+00:00 https://www.trinitydelta.org/board-appointment-2/ 2024-07-12T07:01:39+00:00 https://www.trinitydelta.org/convertible-bond-payment/ 2024-07-19T08:04:01+00:00 https://www.trinitydelta.org/proposed-placing-and-subscription/ 2024-07-22T08:21:41+00:00 https://www.trinitydelta.org/wrap-retail-offer-to-raise-up-to-1m/ 2024-07-22T08:22:45+00:00 https://www.trinitydelta.org/result-of-placing-and-subscription/ 2024-07-22T08:23:49+00:00 https://www.trinitydelta.org/result-of-wrap-retail-offer/ 2024-07-23T06:11:12+00:00 https://www.trinitydelta.org/update-from-iscib1-clinical-advisory-meeting/ 2024-07-24T08:04:06+00:00 https://www.trinitydelta.org/update-on-us-launch/ 2024-08-01T06:49:23+00:00 https://www.trinitydelta.org/2024-interim-results/ 2024-08-01T06:50:46+00:00 https://www.trinitydelta.org/cmo-appointment/ 2024-08-01T06:52:05+00:00 https://www.trinitydelta.org/update-on-fruquintinib-for-2l-gastric-cancer-in-china/ 2024-08-30T16:53:50+00:00 https://www.trinitydelta.org/oral-presentation-of-positive-at278-phase-i-data-at-easd-2024/ 2024-09-04T13:43:52+00:00 https://www.trinitydelta.org/further-update-on-us-launch/ 2024-09-04T14:00:12+00:00 https://www.trinitydelta.org/interim-h124-results/ 2024-09-10T06:10:18+00:00 https://www.trinitydelta.org/positive-at278-phase-i-data-presented-at-easd-2024/ 2024-09-11T07:45:13+00:00 https://www.trinitydelta.org/updated-ava6000-phase-i-clinical-data-at-esmo-2024/ 2024-09-16T15:07:50+00:00 https://www.trinitydelta.org/strategic-partnership-with-pharmajet/ 2024-09-20T14:38:27+00:00 https://www.trinitydelta.org/clinical-data-at-wclc-and-esmo-2024/ 2024-09-23T15:57:45+00:00 https://www.trinitydelta.org/results-for-the-year-ended-30-april-2024/ 2024-09-24T06:11:44+00:00 https://www.trinitydelta.org/japan-approval-for-fruzaqla-in-mcrc/ 2024-09-24T08:01:33+00:00 https://www.trinitydelta.org/interim-h124-results-2/ 2024-09-26T06:24:50+00:00 https://www.trinitydelta.org/h124-interim-results-2/ 2024-09-30T13:52:50+00:00 https://www.trinitydelta.org/elunate-full-subsidy-in-hk-hospital-drug-formulary/ 2024-10-04T09:47:41+00:00 https://www.trinitydelta.org/pipeline-expansion-unveiled-at-eortc-2024/ 2024-10-11T09:27:01+00:00 https://www.trinitydelta.org/us-launch-milestone-payment-triggered/ 2024-10-11T09:28:31+00:00 https://www.trinitydelta.org/cso-appointment/ 2024-10-15T14:22:37+00:00 https://www.trinitydelta.org/high-clinically-meaningful-orr-for-tagrisso-plus-savolitinib-in-phase-ii-savannah-trial/ 2024-10-16T07:26:04+00:00 https://www.trinitydelta.org/preliminary-fy24-results/ 2024-10-18T11:21:36+00:00 https://www.trinitydelta.org/annual-report-and-accounts/ 2024-10-18T11:21:56+00:00 https://www.trinitydelta.org/pursuing-episwitch-as-companion-diagnostics/ 2024-10-18T11:22:19+00:00 https://www.trinitydelta.org/commercial-update-for-fy24/ 2024-10-18T11:22:38+00:00 https://www.trinitydelta.org/cirrp-award-update/ 2024-10-18T11:22:48+00:00 https://www.trinitydelta.org/proposed-fundraising/ 2024-10-18T11:23:03+00:00 https://www.trinitydelta.org/results-of-fundraising/ 2024-10-18T11:23:13+00:00 https://www.trinitydelta.org/uk-clinical-testing-facility-opens/ 2024-10-18T11:23:24+00:00 https://www.trinitydelta.org/collaboration-with-kings-college-london-on-ra/ 2024-10-18T11:23:34+00:00 https://www.trinitydelta.org/partnership-with-the-london-clinic-for-pse-cirt/ 2024-10-18T11:23:43+00:00 https://www.trinitydelta.org/partnership-with-goodbody-clinic-on-pse-test/ 2024-10-18T11:23:56+00:00 https://www.trinitydelta.org/multi-cancer-diagnostic-test-for-dogs/ 2024-10-18T11:24:05+00:00 https://www.trinitydelta.org/pse-test-to-be-used-in-nci-trial/ 2024-10-18T11:24:16+00:00 https://www.trinitydelta.org/half-year-report/ 2024-10-18T11:24:28+00:00 https://www.trinitydelta.org/cirt-receives-clinical-approval-from-nys-clep/ 2024-10-23T07:12:30+00:00 https://www.trinitydelta.org/ceo-appointment/ 2024-10-23T07:14:28+00:00 https://www.trinitydelta.org/strategic-collaboration-with-tempus/ 2024-10-23T07:16:29+00:00 https://www.trinitydelta.org/pipeline-advances-at-eortc-nci-aacr-2024/ 2024-10-24T08:18:28+00:00 https://www.trinitydelta.org/pipeline-expansion/ 2024-10-25T13:27:08+00:00 https://www.trinitydelta.org/data-presented-at-smsna/ 2024-10-25T13:28:17+00:00 https://www.trinitydelta.org/prognostic-covid-severity-test-study-published/ 2024-10-25T13:30:33+00:00 https://www.trinitydelta.org/expert-panel-at-ipf-summit/ 2024-10-25T13:32:49+00:00 https://www.trinitydelta.org/preclinical-rxc008-data-at-ueg/ 2024-10-25T13:33:57+00:00 https://www.trinitydelta.org/prd-spotlight-focusing-on-pipeline-advances/ 2024-11-05T07:37:42+00:00 https://www.trinitydelta.org/encouraging-new-pipeline-development/ 2024-11-05T07:41:26+00:00 https://www.trinitydelta.org/first-commercial-milestone-receipt-from-takeda/ 2024-11-05T09:08:11+00:00 https://www.trinitydelta.org/positive-scope-data-with-scib1/ 2024-11-18T07:18:00+00:00 https://www.trinitydelta.org/appointment-of-interim-cfo-2/ 2024-11-18T07:25:06+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-ash-2024-and-the-2024-esmo-asia-congress/ 2024-11-28T15:57:32+00:00 https://www.trinitydelta.org/launch-by-takeda-of-fruzaqla-fruquintinib-in-japan/ 2024-11-28T15:59:03+00:00 https://www.trinitydelta.org/continued-inclusion-of-orpathys-in-the-china-nrdl-at-current-terms/ 2024-11-28T16:00:40+00:00 https://www.trinitydelta.org/genmab-exercises-option-to-a-second-glymab-commercial-license-agreement/ 2024-12-04T10:46:29+00:00 https://www.trinitydelta.org/china-conditional-approval-for-elunate-in-combination-with-tyvyt-in-advanced-emc/ 2024-12-04T10:48:19+00:00 https://www.trinitydelta.org/response-to-share-price-movement/ 2024-12-06T10:32:32+00:00 https://www.trinitydelta.org/result-of-placing-and-subscription-2/ 2024-12-06T10:34:46+00:00 https://www.trinitydelta.org/china-btd-for-orpathys-tagrisso-in-nsclc-after-disease-progression-on-egfri-therapy/ 2024-12-12T14:07:57+00:00 https://www.trinitydelta.org/completion-of-ava6000-phase-ia-dose-escalation-and-rde-arms/ 2024-12-12T14:10:15+00:00 https://www.trinitydelta.org/directorate-change-funding-update-joint-broker/ 2024-12-16T09:21:28+00:00 https://www.trinitydelta.org/shareholder-loan-and-related-party-transaction/ 2024-12-24T07:58:54+00:00 https://www.trinitydelta.org/milestone-from-takeda-following-first-european-reimbursement-for-fruzaqla/ 2025-01-02T14:39:08+00:00 https://www.trinitydelta.org/us608-million-divestment-of-non-core-jv/ 2025-01-02T14:40:21+00:00 https://www.trinitydelta.org/china-nda-acceptance-with-priority-review-for-orpathys-tagrisso-combo-in-2l-met-amp-nsclc-post-1l-egfri-therapy/ 2025-01-02T14:45:10+00:00 https://www.trinitydelta.org/exclusive-licensing-agreement-for-rtd-speciality-hospital-product-at351/ 2025-01-02T14:46:51+00:00 https://www.trinitydelta.org/modi-1-achieves-early-clinical-validation-in-head-and-neck-cancer/ 2025-01-09T07:23:44+00:00 https://www.trinitydelta.org/orderly-cessation-of-tetris-pharma-operations/ 2025-01-10T07:51:24+00:00 https://www.trinitydelta.org/cfo-appointment/ 2025-01-13T17:39:04+00:00 https://www.trinitydelta.org/full-china-approval-for-savolitinib-in-met-ex14-mnsclc/ 2025-01-14T10:00:07+00:00 https://www.trinitydelta.org/proposed-fundraising-2/ 2025-01-14T19:29:39+00:00 https://www.trinitydelta.org/wrap-retail-offer/ 2025-01-14T19:30:14+00:00 https://www.trinitydelta.org/positive-results-from-wsd4000-home-user-study/ 2025-01-15T07:24:35+00:00 https://www.trinitydelta.org/result-of-placing-and-subscription-3/ 2025-01-15T07:35:59+00:00 https://www.trinitydelta.org/result-of-wrap-retail-offer-2/ 2025-01-17T09:59:39+00:00 https://www.trinitydelta.org/sgc-data-from-ava6000-phase-i-trial/ 2025-01-17T15:27:10+00:00 https://www.trinitydelta.org/issue-of-equity-and-total-voting-rights/ 2025-01-23T08:24:33+00:00 https://www.trinitydelta.org/cirt-real-world-data-presented-at-asco-gi-2025t-of-wrap-retail-offer-3/ 2025-01-23T08:25:54+00:00 https://www.trinitydelta.org/interim-h125-results/ 2025-01-30T07:05:00+00:00 https://www.trinitydelta.org/fy24-trading-update-and-fy25-outlook/ 2025-01-30T07:54:32+00:00 https://www.trinitydelta.org/result-of-gm-and-director-dealings/ 2025-01-31T12:31:50+00:00 https://www.trinitydelta.org/fy24-trading-update/ 2025-02-03T10:45:21+00:00 https://www.trinitydelta.org/crc-test-accurately-detects-cancer-and-polyps/ 2025-02-12T14:55:44+00:00 https://www.trinitydelta.org/partnership-with-regina-maria-to-offer-episwitch-tests-in-romania/ 2025-02-12T14:57:22+00:00 https://www.trinitydelta.org/preliminary-fy24-results-and-notice-of-agm/ 2025-02-28T15:00:33+00:00 https://www.trinitydelta.org/sale-of-launch-diagnostics/ 2025-03-07T10:03:55+00:00 https://www.trinitydelta.org/data-update-for-ava6000/ 2025-03-07T10:05:23+00:00 https://www.trinitydelta.org/partnership-with-biopharmaceutical-company/ 2025-03-13T11:42:59+00:00 https://www.trinitydelta.org/expansion-of-obd-bupa-uk-insurance-partnership/ 2025-03-13T11:43:35+00:00 https://www.trinitydelta.org/completion-of-enrolment-in-china-phase-ii-registration-of-fanregratinib-in-ihc/ 2025-03-19T20:25:56+00:00 https://www.trinitydelta.org/phase-ii-iii-frusica-2-rcc-study-of-fruquintinib-sintilimab-meets-primary-endpoint/ 2025-03-19T20:27:35+00:00 https://www.trinitydelta.org/fy24-results-and-business-update/ 2025-03-19T20:28:25+00:00 https://www.trinitydelta.org/savolitinib-savannah-phase-ii-and-other-data-at-elcc-2025/ 2025-03-20T09:59:26+00:00 https://www.trinitydelta.org/nmpa-conditional-approval-for-tazemetostat-in-r-r-fl/ 2025-03-21T11:39:15+00:00 https://www.trinitydelta.org/completion-of-launch-diagnostics-sale/ 2025-03-27T15:23:37+00:00 https://www.trinitydelta.org/presentations-at-aacr-2025/ 2025-03-27T15:24:18+00:00 https://www.trinitydelta.org/collaboration-with-global-pharmaceutical-partner/ 2025-03-27T15:25:32+00:00 https://www.trinitydelta.org/quarterly-update-q125/ 2025-04-14T16:19:53+00:00 https://www.trinitydelta.org/clinical-data-from-the-ongoing-phase-ii-scope-trial-at-aacr-2025/ 2025-04-14T16:46:19+00:00 https://www.trinitydelta.org/partnership-with-nhs-cancer-vaccine-launch-pad/ 2025-04-14T16:47:03+00:00 https://www.trinitydelta.org/fy24-results/ 2025-04-16T15:39:53+00:00 https://www.trinitydelta.org/fy24-results-2/ 2025-04-22T06:25:04+00:00 https://www.trinitydelta.org/data-from-fap-dox-ava6000-at-aacr-2025/ 2025-05-06T15:57:14+00:00 https://www.trinitydelta.org/preclinical-and-translational-data-from-precision-platform-candidates-at-aacr-2025/ 2025-05-06T15:58:27+00:00 https://www.trinitydelta.org/enrolment-complete-in-china-phase-ii-savolitinib-gastric-cancer-trial/ 2025-05-07T09:54:17+00:00 https://www.trinitydelta.org/data-presentations-at-aacr-2025/ 2025-05-07T09:55:09+00:00 https://www.trinitydelta.org/rights-to-non-ogluo-tetris-products-sold-to-aspire-pharma/ 2025-05-08T10:38:42+00:00 https://www.trinitydelta.org/oxford-lab-accredited-by-ukas/ 2025-05-09T10:29:17+00:00 https://www.trinitydelta.org/partnership-with-skye-bioscience/ 2025-05-19T06:39:06+00:00 https://www.trinitydelta.org/data-presentations-at-asco-2025/ 2025-05-28T07:18:36+00:00 https://www.trinitydelta.org/savolitinib-phase-iii-sachi-data-at-asco-2025/ 2025-06-06T10:15:00+00:00 https://www.trinitydelta.org/china-nda-acceptance-for-fruquintinib-sintilimab-combo-in-rcc/ 2025-06-06T10:16:45+00:00 https://www.trinitydelta.org/preliminary-fy24-results-3/ 2025-06-06T10:18:18+00:00 https://www.trinitydelta.org/new-response-in-ava6000-phase-ib-trial/ 2025-06-19T07:36:11+00:00 https://www.trinitydelta.org/scope-study-update-cohort-4-initiation/ 2025-06-25T07:22:07+00:00 https://www.trinitydelta.org/china-approval-for-savolitinib-osimertinib-in-met-amp-nsclc-after-progression-on-1l-egfri-therapy/ 2025-06-30T09:49:23+00:00 https://www.trinitydelta.org/management-team-appointments/ 2025-07-01T07:15:46+00:00 https://www.trinitydelta.org/q225-business-update/ 2025-07-02T06:42:30+00:00 https://www.trinitydelta.org/board-changes/ 2025-07-08T08:16:07+00:00 https://www.trinitydelta.org/interim-h125-results-2/ 2025-07-08T08:17:40+00:00 https://www.trinitydelta.org/share-price-movement/ 2025-07-11T10:26:47+00:00 https://www.trinitydelta.org/new-scientific-advisory-board/ 2025-07-17T12:25:06+00:00 https://www.trinitydelta.org/equity-fundraise-of-3-25m/ 2025-07-17T12:25:51+00:00 https://www.trinitydelta.org/pfizer-study-on-episwitch-biomarkers/ 2025-07-17T12:27:00+00:00 https://www.trinitydelta.org/genomeweb-to-host-joint-agilent-obd-presentation/ 2025-07-17T12:27:40+00:00 https://www.trinitydelta.org/payment-of-cb-instalment/ 2025-07-21T10:43:42+00:00 https://www.trinitydelta.org/agreement-to-sell-coris-bioconcept/ 2025-07-28T09:49:27+00:00 https://www.trinitydelta.org/new-ava6000-data-at-esmo-2025/ 2025-07-30T10:01:08+00:00 https://www.trinitydelta.org/h125-interim-results/ 2025-08-08T08:28:25+00:00 https://www.trinitydelta.org/collaboration-with-google-cloud/ 2025-08-14T09:13:40+00:00 https://www.trinitydelta.org/enrolment-of-sanovo-china-phase-iii-trial-complete/ 2025-08-20T08:09:21+00:00 https://www.trinitydelta.org/collaboration-with-myriad-genetics/ 2025-08-20T08:10:41+00:00 https://www.trinitydelta.org/strong-phase-ii-data-on-iscib1-in-melanoma/ 2025-08-29T14:07:47+00:00 https://www.trinitydelta.org/appointment-of-acting-ceo/ 2025-08-29T14:08:40+00:00 https://www.trinitydelta.org/amendments-to-convertible-bond-and-equity-fundraise/ 2025-08-29T14:09:48+00:00 https://www.trinitydelta.org/completion-of-sale-of-coris-bioconcept/ 2025-09-01T06:24:12+00:00 https://www.trinitydelta.org/positive-fda-feedback-on-phase-ii-study-design/ 2025-09-04T09:22:46+00:00 https://www.trinitydelta.org/study-confirms-clinical-utility-of-episwitch-cirt/ 2025-09-04T09:24:42+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-wclc-2025-and-csco-2025/ 2025-09-09T06:32:25+00:00 https://www.trinitydelta.org/h125-interim-results-2/ 2025-09-09T06:33:59+00:00 https://www.trinitydelta.org/fy25-results/ 2025-09-11T06:24:49+00:00 https://www.trinitydelta.org/save-the-date-rd-updates-on-october-31-2025/ 2025-09-12T08:00:37+00:00 https://www.trinitydelta.org/trading-business-and-strategic-review-update/ 2025-09-22T13:54:32+00:00 https://www.trinitydelta.org/board-changes-business-update/ 2025-09-22T13:55:00+00:00 https://www.trinitydelta.org/interim-h125-results-3/ 2025-09-25T10:45:13+00:00 https://www.trinitydelta.org/co-development-agreement-monetisation-deal/ 2025-09-25T10:46:00+00:00 https://www.trinitydelta.org/interim-h125-results-4/ 2025-09-30T07:44:53+00:00 https://www.trinitydelta.org/interim-h125-results-5/ 2025-09-30T07:45:38+00:00 https://www.trinitydelta.org/obd-and-uea-develop-test-for-chronic-fatigue/ 2025-10-08T11:27:58+00:00 https://www.trinitydelta.org/obd-in-new-report-on-nhs-prostate-cancer-screening/ 2025-10-14T06:38:01+00:00 https://www.trinitydelta.org/avacta-to-present-data-at-eortc-nci-aacr/ 2025-10-14T06:39:02+00:00 https://www.trinitydelta.org/frusica-2-registration-trial-data-to-be-presented-at-esmo-2025/ 2025-10-14T06:40:59+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-esmo-2025/ 2025-10-14T06:42:20+00:00 https://www.trinitydelta.org/equity-fundraise-of-16-million/ 2025-10-20T09:19:32+00:00 https://www.trinitydelta.org/fundraising-posting-of-circular-notice-of-gm/ 2025-10-22T08:41:26+00:00 https://www.trinitydelta.org/attc-hmpl-a251-data-at-aacr-nci-eortc/ 2025-10-23T09:12:32+00:00 https://www.trinitydelta.org/appointment-of-interim-ceo-and-senior-board-advisor/ 2025-10-30T10:11:40+00:00 https://www.trinitydelta.org/appointment-of-executive-chair-proposed-change-of-name-and-strategy-update/ 2025-10-30T10:11:45+00:00 https://www.trinitydelta.org/board-changes-2/ 2025-10-30T10:11:51+00:00 https://www.trinitydelta.org/parsortix-enables-study-of-cancer-progression/ 2025-10-30T10:11:56+00:00 https://www.trinitydelta.org/eacr-2025-innovation-in-ar-expression-profiling/ 2025-10-30T10:12:01+00:00 https://www.trinitydelta.org/eacr-2025-data-demonstrating-dna-dual-analysis/ 2025-10-30T10:12:06+00:00 https://www.trinitydelta.org/novel-discoveries-into-the-biology-of-cancer/ 2025-10-30T10:12:11+00:00 https://www.trinitydelta.org/preliminary-fy24-results-2/ 2025-10-30T10:12:17+00:00 https://www.trinitydelta.org/new-results-supporting-her2-assay-development-programme/ 2025-10-30T10:12:23+00:00 https://www.trinitydelta.org/update-on-astrazeneca-assay-development-projects-and-eisai-phase-ii-pilot-study/ 2025-10-30T10:12:26+00:00 https://www.trinitydelta.org/novel-findings-using-parsortix/ 2025-10-30T10:12:32+00:00 https://www.trinitydelta.org/analysis-of-ctc-dna-and-ctdna-using-illumina-assay/ 2025-10-30T10:12:38+00:00 https://www.trinitydelta.org/parsortix-used-in-research-paper-from-eth-zurich/ 2025-10-30T10:12:44+00:00 https://www.trinitydelta.org/trading-update-3/ 2025-10-30T10:12:48+00:00 https://www.trinitydelta.org/her2-presentation-at-sabcs/ 2025-10-30T10:12:53+00:00 https://www.trinitydelta.org/parsortix-based-pd-l1-assay-showcased-at-aacr/ 2025-10-30T10:13:00+00:00 https://www.trinitydelta.org/research-on-her2-assay-kit-showcased-at-aacr/ 2025-10-30T10:13:05+00:00 https://www.trinitydelta.org/two-posters-at-eacr/ 2025-10-30T10:13:10+00:00 https://www.trinitydelta.org/parsortix-enriched-ctc-ctdna-in-nsclc-patients/ 2025-10-30T10:13:21+00:00 https://www.trinitydelta.org/ctc-profiling-potential/ 2025-10-30T10:13:25+00:00 https://www.trinitydelta.org/100th-publication-supporting-parsortix/ 2025-10-30T10:13:31+00:00 https://www.trinitydelta.org/h124-report/ 2025-10-30T10:13:36+00:00 https://www.trinitydelta.org/exclusive-agreement-for-dna-ngs-panel/ 2025-10-30T10:13:41+00:00 https://www.trinitydelta.org/agreement-with-recursion-pharmaceuticals/ 2025-10-30T10:13:46+00:00 https://www.trinitydelta.org/data-supporting-fda-approval-published-in-journal/ 2025-10-30T10:13:51+00:00 https://www.trinitydelta.org/independent-parsortix-study/ 2025-10-30T10:13:55+00:00 https://www.trinitydelta.org/result-of-open-offer/ 2025-10-30T10:14:01+00:00 https://www.trinitydelta.org/parsortix-and-assays-being-showcased-at-eacr-2024/ 2025-10-30T10:14:06+00:00 https://www.trinitydelta.org/publication-of-circular/ 2025-10-30T10:14:10+00:00 https://www.trinitydelta.org/results-of-placing-and-subscription/ 2025-10-30T10:14:15+00:00 https://www.trinitydelta.org/proposed-placing-subscription-and-open-offer/ 2025-10-30T10:14:19+00:00 https://www.trinitydelta.org/fy23-prelims/ 2025-10-30T10:14:25+00:00 https://www.trinitydelta.org/study-of-ovarian-cancer-ctcs-using-parsortix/ 2025-10-30T10:14:30+00:00 https://www.trinitydelta.org/second-commercial-agreement-with-astrazeneca/ 2025-10-30T10:14:35+00:00 https://www.trinitydelta.org/new-commercial-agreement-with-astrazeneca/ 2025-10-30T10:14:39+00:00 https://www.trinitydelta.org/us-and-eu-patents-for-innovative-cellkeep-slide/ 2025-10-30T10:14:45+00:00 https://www.trinitydelta.org/parsortix-her2-assay-showcased-at-aacr-2024/ 2025-10-30T10:14:49+00:00 https://www.trinitydelta.org/parsortix-at-european-breast-cancer-conference/ 2025-10-30T10:14:54+00:00 https://www.trinitydelta.org/phase-ia-faridoxorubicin-data-at-esmo/ 2025-11-04T08:56:41+00:00 https://www.trinitydelta.org/preclinical-data-at-aacr-nci-eortc-2025/ 2025-11-04T09:04:21+00:00 https://www.trinitydelta.org/completion-of-placing-and-tvr/ 2025-11-04T09:05:13+00:00 https://www.trinitydelta.org/cenhanced-ip-coverage-at278-oral-peptide-programme/ 2025-11-04T09:06:55+00:00 https://www.trinitydelta.org/expert-consensus-on-ctcs-and-update-on-funding/ 2025-11-04T09:07:59+00:00 https://www.trinitydelta.org/pipeline-and-business-progress-highlighted-at-rd-updates-event/ 2025-11-04T09:09:15+00:00 https://www.trinitydelta.org/proof-of-concept-study-using-roche-tissue-diagnostics-workflow/ 2025-11-05T08:02:00+00:00 https://www.trinitydelta.org/global-saffron-phase-iii-enrolment-complete/ 2025-11-05T08:22:56+00:00 https://www.trinitydelta.org/presentation-of-phase-ii-iscib1-scope-data-at-sitc-2025/ 2025-11-07T13:33:07+00:00 https://www.trinitydelta.org/fundraise-of-2-75m/ 2025-11-13T07:40:09+00:00 https://www.trinitydelta.org/further-update-on-funding/ 2025-11-18T12:50:34+00:00 https://www.trinitydelta.org/qiagen-collaboration-and-co-marketing-agreement/ 2025-11-18T12:51:16+00:00 https://www.trinitydelta.org/proposed-placing-and-subscription-2/ 2025-11-24T19:14:43+00:00 https://www.trinitydelta.org/result-of-oversubscribed-placing-and-subscription/ 2025-11-25T08:23:36+00:00 https://www.trinitydelta.org/launch-of-retail-offer/ 2025-11-25T08:24:32+00:00 https://www.trinitydelta.org/clinical-data-at-esmo-asia-2025-and-ash-2025/ 2025-11-28T09:18:55+00:00 https://www.trinitydelta.org/update-to-admission-of-fundraising-shares/ 2025-12-02T15:08:14+00:00 https://www.trinitydelta.org/result-of-retail-offer/ 2025-12-02T15:08:57+00:00 https://www.trinitydelta.org/additional-subscription/ 2025-12-02T15:09:33+00:00 https://www.trinitydelta.org/updated-phase-ii-scope-data/ 2025-12-09T07:42:43+00:00 https://www.trinitydelta.org/board-change-3/ 2025-12-14T19:42:22+00:00 https://www.trinitydelta.org/patent-notice-of-allowance-granted-for-china/ 2025-12-14T19:42:59+00:00 https://www.trinitydelta.org/expanded-coverage-on-nrdl-and-inclusion-in-the-first-commercial-insurance-drug-list-in-china/ 2025-12-14T19:44:32+00:00 https://www.trinitydelta.org/statement-re-share-price-update-on-episwitch-pse/ 2025-12-14T19:46:04+00:00 https://www.trinitydelta.org/preliminary-fy25-results/ 2025-12-16T14:23:00+00:00 https://www.trinitydelta.org/initiation-of-global-clinical-development-of-attc-candidate-hmpl-a251-in-solid-tumours/ 2025-12-17T08:14:00+00:00 https://www.trinitydelta.org/faridoxorubicin-phase-ib-sgc-data/ 2025-12-17T08:15:13+00:00 https://www.trinitydelta.org/new-ava6103-pharmacology-data/ 2025-12-18T08:54:16+00:00 https://www.trinitydelta.org/china-nda-acceptance-with-priority-review-status-for-fanregratinib-in-2l-ihcc/ 2025-12-29T17:17:43+00:00 https://www.trinitydelta.org/china-nda-acceptance-with-priority-review-status-for-savolitinib-in-metamp-gastric-cancer/ 2025-12-30T14:41:04+00:00 https://www.trinitydelta.org/initiation-of-phase-iii-part-of-phase-ii-iii-trial-of-surufatinib-camrelizumab-in-1l-pdac/ 2026-01-07T18:27:46+00:00 https://www.trinitydelta.org/positive-topline-results-of-china-phase-iii-eslim-02-trial-for-sovleplenib-in-waiha/ 2026-01-07T18:29:23+00:00 https://www.trinitydelta.org/positive-results-from-wsd4000-early-feasibility-study/ 2026-01-13T09:14:09+00:00 https://www.trinitydelta.org/year-end-trading-update-2/ 2026-01-20T14:34:44+00:00 https://www.trinitydelta.org/fda-clearance-of-ind-application-for-ava6103/ 2026-01-21T07:24:01+00:00 https://www.trinitydelta.org/fda-clearance-of-ind-application-for-global-phase-iii-trial-of-iscib1-in-advanced-melanoma/ 2026-01-26T07:23:50+00:00 https://www.trinitydelta.org/h126-interim-results-and-business-update/ 2026-01-29T07:39:21+00:00 https://www.trinitydelta.org/faridoxorubicin-programme-clinical-updates/ 2026-02-04T07:44:31+00:00 https://www.trinitydelta.org/trading-update-4/ 2026-02-04T07:45:16+00:00 https://www.trinitydelta.org/fy25-business-update/ 2026-02-09T15:57:37+00:00 https://www.trinitydelta.org/appointment-of-cso-2/ 2026-02-09T15:59:08+00:00 https://www.trinitydelta.org/precision-payload-delivery-advantage-over-adc/ 2026-02-24T07:43:57+00:00 https://www.trinitydelta.org/initiation-of-global-trial-of-attc-candidate-hmpl-a580/ 2026-03-04T09:05:58+00:00 https://www.trinitydelta.org/obd-to-present-at-pmwc-2026/ 2026-03-04T09:07:23+00:00 https://www.trinitydelta.org/fy25-results-and-business-update/ 2026-03-05T18:08:44+00:00 https://www.trinitydelta.org/update-on-tazverik-in-china/ 2026-03-12T08:34:03+00:00 https://www.trinitydelta.org/ava6103-fap-exd-phase-i-study-opening/ 2026-03-16T07:24:06+00:00 https://www.trinitydelta.org/presentations-of-precision-platform-candidates-at-aacr-2026/ 2026-03-17T16:29:07+00:00 https://www.trinitydelta.org/formal-grant-of-us-patent/ 2026-03-18T10:43:38+00:00 https://www.trinitydelta.org/positive-eroxon-eroxon-intense-hut-results/ 2026-03-24T13:48:11+00:00 https://www.trinitydelta.org/initiation-of-hmpl-760-china-phase-iii-trial-in-r-r-dlbcl/ 2026-03-24T13:50:01+00:00 https://www.trinitydelta.org/proposed-fundraise-to-raise-approximately-10m/ 2026-03-27T07:35:09+00:00 https://www.trinitydelta.org/result-of-oversubscribed-fundraise/ 2026-03-27T07:35:58+00:00 https://www.trinitydelta.org/cfo-transition/ 2026-04-07T12:06:09+00:00 https://www.trinitydelta.org/first-patient-treated-in-phase-i-trial-of-ava6103/ 2026-04-07T12:07:09+00:00 https://www.trinitydelta.org/avacta-announces-science-day-2026/ 2026-04-08T06:35:20+00:00 https://www.trinitydelta.org/q126-business-update/ 2026-04-09T06:53:11+00:00 https://www.trinitydelta.org/data-to-be-presented-at-aacr-2026/ 2026-04-09T06:54:56+00:00 https://www.trinitydelta.org/aacr-data-underline-ava6103-profile/ 2026-04-21T08:54:31+00:00 https://www.trinitydelta.org/fda-fast-track-designation-for-iscib1/ 2026-04-28T11:15:28+00:00 https://www.trinitydelta.org/china-nda-acceptance-with-priority-review-status-and-btd-for-sovleplenib-in-waiha/ 2026-04-30T08:29:38+00:00 https://www.trinitydelta.org/precision-payload-release-vs-approved-adcs/ 2026-05-07T07:45:21+00:00 https://www.trinitydelta.org/fy25-results-2/ 2026-05-19T10:42:29+00:00 https://www.trinitydelta.org/china-nmpa-approval-for-fruquintinib-sintilimab-combination-in-rcc/ 2026-05-21T17:29:53+00:00 https://www.trinitydelta.org/clinical-data-to-be-presented-at-the-2026-asco-annual-meeting/ 2026-05-22T12:23:14+00:00 https://www.trinitydelta.org/updated-clinical-data-on-ava6000-in-salivary-gland-cancers-at-asco-2026/ 2026-06-05T06:50:36+00:00 https://www.trinitydelta.org/oversubscribed-strategic-equity-fundraise-of-9m/ 2026-06-05T06:51:39+00:00 https://www.trinitydelta.org/sovleplenib-eslim-02-phase-iii-data-in-waiha-at-eha-2026-congress/ 2026-06-15T14:57:23+00:00 https://www.trinitydelta.org/year-to-date-business-update-pre-agm/ 2026-06-22T14:00:41+00:00 https://www.trinitydelta.org/pivotal-phase-ii-fanregratinib-data-in-ihcc-at-esmo-gi-2026/ 2026-06-25T14:40:51+00:00 https://www.trinitydelta.org/fda-agreement-on-pivotal-trial-design-for-ava6000/ 2026-06-25T14:41:54+00:00 https://www.trinitydelta.org/platform-validating-data-with-faridoxorubicin/ 2026-06-25T14:42:47+00:00 https://www.trinitydelta.org/response-to-press-speculation/ 2026-06-26T14:11:40+00:00 https://www.trinitydelta.org/new-us-commercial-partner/ 2026-06-29T12:30:12+00:00 https://www.trinitydelta.org/highly-positive-data-from-wsd4000-studies/ 2026-06-30T12:53:09+00:00 https://www.trinitydelta.org/appointment-of-ceo/ 2026-06-30T12:54:37+00:00 https://www.trinitydelta.org/h126-interim-results/ 2026-06-30T12:55:57+00:00 https://www.trinitydelta.org/us-contract-sales-partnership/ 2026-06-30T12:56:29+00:00 https://www.trinitydelta.org/nmpa-approval-for-orpathys-in-metamp-gastric-cancer/ 2026-07-02T12:28:44+00:00 https://www.trinitydelta.org/new-deputy-chair/ 2026-07-09T09:05:08+00:00 https://www.trinitydelta.org/accelerated-amortized-payment-of-bond-instalment/ 2026-07-09T09:07:01+00:00 https://www.trinitydelta.org/proposed-uk-placing/ 2026-07-23T07:39:13+00:00 https://www.trinitydelta.org/launch-of-retail-offer-2/ 2026-07-23T07:39:52+00:00 https://www.trinitydelta.org/neuphoria-merger-and-financing/ 2026-07-23T07:40:36+00:00 https://www.trinitydelta.org/oversubscribed-uk-placing-raises-13m/ 2026-07-23T15:36:01+00:00 https://www.trinitydelta.org/result-of-retail-offer-and-total-voting-rights/ 2026-07-27T06:52:56+00:00 https://www.trinitydelta.org/first-commercial-agreement-for-episwitch-orion/ 2026-07-28T14:42:08+00:00 https://www.trinitydelta.org/eroxon-intense-eu-market-launch-clearance/ 2026-07-31T08:01:46+00:00 https://www.trinitydelta.org/fundraising-posting-of-circular-notice-of-gm-2/ 2026-08-13T09:35:42+00:00 https://www.trinitydelta.org/partnership-with-dubai-london-clinics-hospitals/ 2026-08-13T09:36:36+00:00 https://www.trinitydelta.org/h126-interim-results-2/ 2026-08-13T09:38:57+00:00 https://www.trinitydelta.org/positive-top-line-saffron-phase-iii-data/ 2026-08-17T16:06:36+00:00 https://www.trinitydelta.org/uk-mhra-cta-for-iscib1-phase-iii-in-advanced-melanoma/ 2026-08-19T07:31:35+00:00